



## **CURRICULUM VITAE** (February 2026)

**Prof. Prof. GAETANO CARAMORI, MD, PhD,**  
**Fellow of the European Respiratory Society (FERS),**  
**Royal Society of Medicine Overseas Fellow, UK**  
**Pneumologia**

**Dipartimento di Medicina e Chirurgia (DIMEC)**

**Via A. Gramsci, 14 , 43126 Parma, [mc.unipr.it](http://mc.unipr.it)**

**Università degli Studi di Parma**

**Via Università, 12, 43121 Parma, Italy [www.unipr.it](http://www.unipr.it)**

**Mobile: (+39) 349/0945733;**

**E-mail: [gaetano.caramori@unipr.it](mailto:gaetano.caramori@unipr.it);**

**<https://profpneumologia.it/collegio/componenti/gaetano-caramori/>**

**Clinica Pneumologica, AOPR, Italy**

**(<https://www.ao.pr.it/curarsi/reparti-e-servizi-sanitari/clinica-pneumologica/>)**

**Laboratorio di Ricerca di Pneumologia Molecolare Traslazionale**

**(<https://mc.unipr.it/en/node/4170>)**

**Microbiome Research Hub**

**(<https://www.microbiomeresearchhub.com/prof-gaetano-caramori>)**

**2. BORN:** Ferrara, 16 November 1961.

**3. HOME ADDRESS:** Via Boschetto 3/ interno 8, 44124, Ferrara, Italy.

### **4. CITIZENSHIP**

Italian.

### **5. DEGREES**

- Degree in Medicine and Surgery (MD), 110/110 summa cum laude, 1992, University of Modena, Italy
- Specialisation in Respiratory Diseases, 50/50 summa cum laude, 1996, University of Ferrara, Italy
- Philosophical Doctor (PhD) in Experimental Respiratory Pathophysiology, 2001, University of Parma, Italy
- Assistant Professor in Respiratory Diseases, 2006-2011, University of Ferrara, Italy
- Associate Professor in Respiratory Diseases, 2011-April 2017, University of Ferrara, Italy
- Honorary Full Professor in Respiratory Diseases, 2013-2016

- Full Professor in Respiratory Diseases, University of Messina, Italy May 2017-October 2023
- Full Professor in Respiratory Diseases, University of Parma, Italy November 2023-

## **6. SCIENTIFIC SOCIETIES**

European Respiratory Society, 1993-  
 2013-2015 Chair of the scientific Group 5.01 (Airway Pharmacology and Treatment).  
 2015- Member of the New York Academy of Sciences, USA  
 2015- Member of the Società Italiana di Pneumologia/Italian Respiratory Society (SIP/IRS)  
 2015-2019, Member of the American College of Chest Physicians  
 2016, Fellow of European Respiratory Society (FERS) Award  
 2017-2021 Member of the European Academy of Allergy and Clinical Immunology  
 2017- Overseas Member of the Royal Society of Medicine, UK  
 2001- Honorary member of the staff at the Airways Disease Section of the National Heart and Lung Institute at the Imperial College London, London, UK.

## **7. REFEREE OF SCIENTIFIC JOURNALS**

Acta Biomedica Atenei Parmensis, 2023-  
 Acta Radiologica, 2011-  
 American Journal of Physiology, 2009-  
 American Journal of Respiratory and Critical Care (formerly known as American Review of Respiratory Diseases and American Journal of Respiratory and Critical Care Medicine), 2000-  
 Apoptosis, 2010-  
 Biomarkers in Medicine, 2013-  
 Bioscience Reports, 2010-  
 BMC Pulmonary Medicine, 2010-  
 BMC Research Notes, 2012-  
 BMJ Open, 2013-  
 Breathe, 2006-  
 British Journal of Pharmacology, 2000-  
 Cell Adhesion and Communication, 2010-  
 Chest, 2006-  
 Clinical and Experimental Allergy, 2007-  
 Clinical and Experimental Immunology, 2010-  
 Clinical Drug Investigation, 2005-  
 Clinical Lung Cancer, 2011-  
 Clinical Physiology and Functional Imaging, 2006-  
 Clinical Respiratory Journal, 2010-  
 COPD, Journal of Chronic Obstructive Pulmonary Disease, 2012-  
 Cough, 2007-  
 Current Cancer Drug Targets, 2011-  
 Current Clinical Pharmacology, 2010-  
 Current Medicinal Chemistry, 2010-  
 Current Opinion in Investigational Drugs, 2008-  
 Current Pharmaceutical Design, 2011-  
 Drug Discovery Today, 2005-  
 Drug News and Perspectives, 2010-  
 Endocrinology, 2007-  
 European Journal of Cardiovascular Prevention and Rehabilitation, 2010-

European Journal of Internal Medicine, 2012-  
European Respiratory Diseases, 2011-  
European Respiratory Journal, 2004-  
Expert Opinion in Investigational Drugs, 2012-  
Expert Opinion in Pharmacotherapy, 2005-  
Expert Opinion on Therapeutic Targets, 2010-  
Expert Review of Clinical Immunology, 2008-  
Expert Review of Respiratory Medicine, 2011-  
FASEB Journal, 2013-  
FEMS Immunology and Medical Microbiology, 2008-  
Frontiers in Bioscience, 2008-  
Future Lipidology, 2008-  
Health Policy and Systems, 2007-  
Histology and Histopathology, 2010-  
Journal of Applied Physiology, 2007-  
Journal of Chronic Obstructive Pulmonary Disease, 2005-  
Journal of Clinical Medicine and Research, 2011-  
Journal of Cytology and Histology, 2012-  
Journal of Immunology, 2006-  
Journal of Inflammation (London), 2010-  
Journal of Medical Hypotheses and Ideas, 2012-  
Journal of Occupational Medicine and Toxicology, 2005-  
Journal of Pharmacology and Experimental Therapeutics, 2006-  
Journal of Thoracic Diseases, 2014-  
Key Opinions, 2012-  
IDrugs, 2003-  
Inflammation and Allergy: Drug Targets, 2008-  
International Archives of Allergy and Immunology, 2006-  
International Journal of COPD, 2006-  
International Journal of Environmental Research and Public Health, 2009-  
International Journal of Experimental Pathology, 2009-  
International Journal of Health and Geographics, 2008-  
International Journal of Molecular Sciences, 2011-  
Lancet, 2009-  
Lancet Respiratory Medicine, 2017-  
Lung, 2007-  
Lung Cancer, 2015-  
Lung India, 2011-  
Molecular Medicine, 2011-  
Monaldi Archives for Chest Disease, 1993-  
Multidisciplinary Respiratory Medicine, 2016-  
Open Respiratory Medicine Journal, 2012-  
Patient Adherence and Preference, 2014-  
Pharmacology, 2011-  
Pharmacological Research, 2006-  
PLoS Medicine, 2004-  
PLoS One, 2011-  
Primary Care Respiratory Journal, 2006-  
Pulmonary Pharmacology and Therapeutics (formerly termed Pulmonary Pharmacology),  
2002-  
Rassegna di Patologia dell'Apparato Respiratorio, 1995-

Recent Patents on Inflammation and Allergy Drug Discovery, 2012-  
Regulatory Peptides, 2008-  
Respiration, 2000-  
Respiratory Medicine, 2005-  
Respiratory Research, 2006-  
Respirology, 2010-  
Southern Medical Journal, 2007-  
Stem Cells Reviews and Reports, 2012-  
Therapeutic Advances in Respiratory Disease, 2018-  
Thorax, 2003-  
The Open Pathology Journal, 2008-2013 (discontinued journal)  
The Open Respiratory Medicine, 2012-  
The Scientific World Journal, 2011-  
World Journal of Surgical Oncology, 2006-  
Yonsei Medical Journal, 2011-

## **8. EDITORIAL BOARDS OF SCIENTIFIC JOURNALS**

### **Current positions**

#### **Senior Editor:**

Journal of Inflammation (<https://journal-inflammation.biomedcentral.com/about/editorial-board>), 2009-.

#### **Editorial Board Member:**

##### **Associate Editor**

COPD, Journal of Chronic Obstructive Pulmonary Disease, 2018- (<https://www.tandfonline.com/journals/icop20/about-this-journal#editorial-board>)

Acta Biomedica Atenei Parmensis ([Editorial Team | Acta Biomedica Atenei Parmensis \(mattioli1885journals.com\)](http://www.mattioli1885journals.com)), 2023-

#### **Previous positions:**

**Editorial Board Member of Pulmonary Pharmacology and Therapeutics, 2016-2023.**

##### **COPD Reporter Team Leader**

Respiratory Research, 2000-2002.

##### **Editore Associato**

Rassegna di Patologia dell'Apparato Respiratorio, 1997-2006

##### **Advisory Board Member:**

Advances in Therapy

(<http://www.springer.com/springer+healthcare/journal/12325?detailsPage=editorialBoard>), 2016-2020

##### **Editorial Board Member**

COPD Research and Practice, 2015-2017 (discontinued Journal)

The Open Pathology Journal, 2008-2014 (discontinued Journal)

BMC Pulmonary Medicine (<https://bmcpulmmed.biomedcentral.com/about/editorial-board>), 2018.

Inflammation and Allergy: Drug Targets, 2008-2015 (discontinued Journal)

## **9. REFEREE FOR NATIONAL AND INTERNATIONAL INSTITUTIONS**

Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca (ANVUR) (<http://www.anvur.org/index.php?lang=it>).

Barcelona Respiratory Network (<http://brn.cat/en/>).

Dutch Cancer Society (<https://www.kwf.nl/english/pages/default.aspx>).

European Respiratory Society (ERS) College of Experts.

European Lung Foundation.

FWO (Research Foundation Flanders) (<http://www.fwo.be/en/>).  
HRA ([http://www.hra.uk.com/media\\_awards.php](http://www.hra.uk.com/media_awards.php)).  
Imperial College London (<https://www.imperial.ac.uk/>).  
Medical Research Council (MRC) (<http://www.mrc.ac.uk/>).  
Ministero dell'Istruzione, dell'Università e della Ricerca (MIUR) (<http://www.istruzione.it/>).  
Netherlands Asthma Foundation (<https://www.longfonds.nl/>).  
The Netherlands Organization for Health Research and Development (<http://www.zonmw.nl/en/>).  
The Royal Society of Medicine (<https://www.rsm.ac.uk/>).  
The University of Sydney (<http://sydney.edu.au/>).  
TV3 Marathon (<http://www.tv3.cat/marato/en/>).  
University of Wolverhampton (<http://www.wlv.ac.uk/>).

## 10. INTERNATIONAL SCIENTIFIC COMMITTEE

Immune Pharma (<http://www.immunepharma.it/about-us/international-scientific-committee/>).

## 9. REFERENCES

**Ian M. Adcock**, Full Professor of Respiratory Cell and Molecular Biology, Airway Disease Section, Department of Thoracic Medicine, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK, e-mail: [ian.adcock@imperial.ac.uk](mailto:ian.adcock@imperial.ac.uk), <http://www.imperial.ac.uk/people/ian.adcock>

**Peter J. Barnes**, Full Professor of Thoracic Medicine, Margaret Turner-Warwick Chair, Head of the Airway Disease Section, Former President of the European Respiratory Society, Department of Thoracic Medicine, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK, e-mail: [p.j.barnes@imperial.ac.uk](mailto:p.j.barnes@imperial.ac.uk), <http://www.imperial.ac.uk/people/p.j.barnes>

**Alfredo Antonio Chetta**, Professore Ordinario Fuori Ruolo di Malattie dell'Apparato Respiratorio, Dipartimento DIMEC, Università degli Studi di Parma, e-mail: [alfredoantonio.chetta@unipr.it](mailto:alfredoantonio.chetta@unipr.it)

**Kian Fan Chung**, Full Professor of Respiratory Medicine, Department of Thoracic Medicine, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK, e-mail: [f.chung@imperial.ac.uk](mailto:f.chung@imperial.ac.uk), <http://www.imperial.ac.uk/people/f.chung>

**Giuseppe Girbino**, Professore Ordinario Fuori Ruolo di Malattie dell'Apparato Respiratorio, Dipartimento BIOMORF, Università degli Studi di Messina, e-mail: [ggirbino@gmail.com](mailto:ggirbino@gmail.com)

## Main areas of research

My research interests have focused from the beginning only on bronchial asthma and chronic obstructive pulmonary disease (COPD). I always tried to apply on human translational studies modern molecular and cellular techniques to the investigation of asthma and COPD patients, particularly through the combination of molecular techniques with clinical studies.

I have been particularly interested to investigate the inflammatory and anti-inflammatory mechanisms in carefully characterised phenotypes of patients with asthma and COPD.

My initial research interest on the role of neurogenic inflammation, cytokines, chemokines, proteases, adenosine, and mucins secretion in these diseases has more recently shifted to the study of the role of transcription factors and kinases in the regulation of inflammatory genes in the lower airways and the effect of oxidative/nitrosative stress on cell survival and death, DNA damage and repair and glucocorticoid-resistance in the lung of patients with asthma and COPD.

I have been particularly interested in the regulation of the activity of transcription factors involved in modulating airway and lung inflammation (AP-1, NF- $\kappa$ B, STAT1, STAT3) and Th1/Tc1/Th2/Tc2/Th17/Treg differentiation (GATA-3, STAT4, STAT6, T bet, RORC2, erm, Foxp3) in primary cells and tissues from the site of disease in asthma and COPD and tuberculosis and pulmonary hypertension and how these transcription factors modulate chromatin remodeling (HATs/HDACs balance).

More recently I have been investigating the lung of patients with stable COPD and control subjects the kinases involved in causing glucocorticoid resistance and the autoimmunity mechanisms involved in the progression of the disease.

My studies have already been shown to be relevant to explain *in vivo* the mechanism of action of many drugs (such as glucocorticoids and theophylline) commonly used for the treatment of asthma and COPD.

In the latest decade I also have been involved in many studies to investigate *in vitro*, in animal models and in human subjects the causes and the molecular mechanisms of asthma and COPD exacerbations, particularly in the human model of rhinovirus induced asthmatic exacerbations.

My latest research interests are concentrated on characterizing the stem cells involved in COPD lung repair/fibrogenesis/oncogenesis and on the molecular links between DNA damage and repair and lung inflammation and carcinogenesis in COPD and IPF.

Prof. GAETANO CARAMORI, MD, PhD,  
Fellow of the European Respiratory Society (FERS),  
Royal Society of Medicine Overseas Fellow, UK  
Pneumologia  
Dipartimento di Medicina e Chirurgia (DIMEC)  
Via A. Gramsci, 14 , 43126 Parma, [mc.unipr.it](http://mc.unipr.it)  
Università degli Studi di Parma  
Via Università, 12, 43121 Parma, Italy [www.unipr.it](http://www.unipr.it)  
Mobile: (+39) 349/0945733;  
E-mail: [gaetano.caramori@unipr.it](mailto:gaetano.caramori@unipr.it);  
<https://profpneumologia.it/collegio/componenti/gaetano-caramori/>  
Clinica Pneumologica, AOPR, Italy  
(<https://www.ao.pr.it/curarsi/reparti-e-servizi-sanitari/clinica-pneumologica/>)  
Laboratorio di Ricerca di Pneumologia Molecolare Traslazionale  
(<https://mc.unipr.it/en/node/4170>)  
Microbiome Research Hub  
(<https://www.microbiomeresearchhub.com/prof-gaetano-caramori>)

## LIST OF PUBLICATIONS

a. Publications in peer-reviewed Journals listed in PubMed(<http://www.ncbi.nlm.nih.gov/pubmed/?term=caramori+g>) and/or (<https://scholar.google.com/citations?user=iAKMCWwAAAAJ&hl=en&oi=ao>)  
Scopus Author ID: 7003847659  
Orcid ID: [orcid.org/0000-0002-9807-327X](https://orcid.org/0000-0002-9807-327X)  
Rank 451 in Top Italian Scientists in Clinical Sciences  
(<https://topitalianscientists.org/tis/4093/Gaetano-Caramori-Top-Italian-Scientist-in-Clinical-Sciences>)

Orcid ID: [orcid.org/0000-0002-9807-327X](https://orcid.org/0000-0002-9807-327X)

Web of Science ResearcherID: AAS-8611-2020.

Scopus Author ID: 7003847659

**H-index (indice di Hirsch) totale=61** ( [www.scopus.com](http://www.scopus.com))

H-index (Google Scholar) =61  
(<https://scholar.google.it/citations?user=HuNo6FYAAAAJ&hl=it>)  
i10-index (Google Scholar)  
(<https://scholar.google.it/citations?user=iAKMCWwAAAAJ&hl=it>):150

1. **Caramori G**, Fabbri L (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Asthma death. Monaldi Arch Chest Dis 1995;50:256-257.
2. Fabbri L, **Caramori G**, Cosma P, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4).. Methotrexate in the treatment of systemic glucocorticoid dependent severe persistent asthma: a word of caution. Monaldi Arch Chest Dis 1996;51:130-137.

3. Fabbri LM, Piattella M, **Caramori G**, Ciaccia A (Pharmacology and Pharmacy 7/353, Impact Factor 14.4, 2024, Q1). Oral versus inhaled antiasthmatic therapy: pro, cons and combinations. *Drugs* 1996;52(suppl 6):20-28.
4. Fabbri LM, **Caramori G**, Beghè B, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Role of leukotrienes in asthma pathogenesis. *Monaldi Archiv Chest Dis* 1996;51:548-555.
5. Ciaccia A, **Caramori G**, Ferrari M, Facchini FM, Fabbri L (Allergy 2/39, Impact Factor 11.3, 2024, Q1). Pulmonary vasculitis: classification, clinical features and management. *Clin Rev Allergy Immunol* 1997;15:73-95.
6. Mapp CM, Lucchini RE, Facchini F, Turato G, Saetta M, **Caramori G**, Ciaccia A, Maestrelli P, Springall DR, Polak JM, Fabbri LM (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. *Am J Respir Crit Care Med* 1997;156:1963-1968.
7. Fugagnoli A, Castelletti ML, **Caramori G**, Romagnoli M, Fabbri LM, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Subcutaneous emphysema of the chest wall: a case with unusual presentation. *Monaldi Archiv Chest Dis* 1997;52:447-449.
8. Fabbri LM, **Caramori G**, Beghè B, Papi A, Ciaccia A (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Physiologic consequences of long-term inflammation. *Am J Respir Crit Care Med* 1998;157(suppl):S195-S198.
9. Fabbri LM, **Caramori G**, Beghè B, Papi A, Ciaccia A (Respiratory System 46/108, Impact Factor 2.8, 2024, Q2). Chronic obstructive pulmonary disease international guidelines. *Curr Opin Pulm Med* 1998;4:76-84.
10. Fabbri LM, Beghè B, **Caramori G**, Papi A, Saetta M (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Similarities and discrepancies between exacerbations of asthma and chronic obstructive pulmonary disease. *Thorax* 1998;53:803-808.
11. Aleotti A, Cervellati F, Bovolenta MR, Zago S, Orvieto E, **Caramori G**, Bezzi T (Pathology 64/90, Impact Factor 1.2, 2024, Q3). Birbeck granules: contribution to the comprehension of intracytoplasmic evolution. *J Submicrosc Cytol Pathol* 1998;30:295-298. (currently the Journal has merged with, and continued as, *Ultrastructural Pathology*)
12. Lim S, Fischer A, Oates T, Groneburg D, **Caramori G**, Mattos W, Adcock IM, Barnes PJ, Chung KF (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Expression of heme-oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: effects of inhaled corticosteroids. *Am J Respir Crit Care Med* 2000;162:1912-1918.
13. Ito K, Lim S, **Caramori G**, Chung K, Barnes PJ, Adcock IM (Biology 17/108, Impact Factor 4.2, 2024 Q1). Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. *FASEB J* 2001;15:1110-1112. The Full-length version of this article is also available, published online February 5, 2001 as doi:10.1096/fj.00-0432fje. Available online <http://www.fasebj.org/>
14. Di Stefano A, Capelli A, Lusuardi M, **Caramori G**, Balbo P, Ioli F, Balbi B, Chung KF, Adcock IM, Barnes PJ, Donner CF (Allergy 7/39, Impact Factor 5.2, 2024, Q1). Decreased T-lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. *Clin Exp Allergy* 2001;31:893-902.
15. Pasquini C, Braccioni F, Calia N, Ravenna F, Castelletti ML, Papi A, **Caramori G**, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Congenital diaphragmatic hernia simulating a pleural liposarcoma. *Monaldi Archiv Chest Dis* 2001;56:121-123.
16. **Caramori G**, Lim S, Ito K, Tomita K, Oates T, Jazwari E, Chung K, Barnes PJ, Adcock IM (Respiratory System 2/108, Impact Factor 21, 2024, Q1). GATA transcription factors

expression in T cells, monocytes and bronchial biopsies of normal and asthmatic subjects. *Eur Respir J* 2001;18:466-473.

17. Lim S, Tomita K, **Caramori G**, Jatakanon A, Oliver B, Keller A, Adcock IM, Chung K, Barnes PJ (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. *Am J Respir Crit Care* 2001;164:273-276. Erratum in: *Am J Respir Crit Care* 2004;170:345. Carramori G [corrected to Caramori G].

18. Adcock IM, **Caramori G** (Immunology 98/184, Impact Factor 3, 2024, Q3). Cross-talk between pro-inflammatory transcription factors and glucocorticoids. *Immunol Cell Biol* 2001;79:376-384.

19. Oliver B, Tomita K, **Caramori G**, Keller A, Kelly C, Meah S, Adcock IM, Chung KF, Barnes PJ, Lim S (Allergy 1/39, Impact Factor 12, 2024, Q1). Low-dose theophylline does not exert its anti-inflammatory effects in mild asthma through upregulation of interleukin-10 in alveolar macrophages. *Allergy* 2001;56:1087-1090.

20. Ravenna F, **Caramori G**, Papi A, Benea G, Adcock IM, Barnes PJ, Ciaccia A (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). An unusual case of congenital short trachea with very long bronchi mimicking bronchial asthma. *Thorax* 2002;57:372-373.

21. Ito K\*, **Caramori G\***, Lim S, Oates T, Chung KF, Barnes PJ, Adcock IM (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Expression and activity of histone deacetylases in human asthmatic airways. *Am J Respir Crit Care* 2002;166:392-396. \*Both Authors contributed equally to this work.

22. Ito K, Lim S, **Caramori G**, Cosio B, Chung KF, Adcock IM Barnes PJ (Multidisciplinary Sciences 14/136, Impact Factor 9.1, 2024, Q1). A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. *P Natl Acad Sci USA* 2002;99:8921-8926.

23. Tomita K, **Caramori G**, Lim S, Ito K, Hanazawa T, Oates T, Jazrawi E, Chung KF, Barnes PJ, Adcock IM (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Increased p21<sup>CIP1/WAF1</sup> and bcl-xL expression and reduced apoptosis in alveolar macrophages from smokers. *Am J Respir Crit Care* 2002;166:724-731.

24. Di Stefano A, **Caramori G**, Oates T, Capelli A, Lusuardi M, Gnemmi I, Ioli F, Balbo P, Brun P, Chung KF, Donner CF, Barnes PJ, Adcock IM (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Increased expression of NF- $\kappa$ B in bronchial biopsies from smokers and patients with chronic obstructive pulmonary disease (COPD). *Eur Resp J* 2002;20:556-563.

25. Eynott P, Groneberg D, **Caramori G**, Adcock I, Donnelly L, Kharitonov S, Barnes P, Chung K (Pharmacology and Pharmacy System 54/353, Impact Factor 4.7, 2024, Q1). Role of nitric oxide in allergic inflammation and bronchial hyperresponsiveness. *Eur J Pharmacol* 2002;452:123-133.

26. Roche N, Stirling RG, Lim S, Oliver BG, Oates T, Jazrawi E, **Caramori G**, Chung KF (Allergy 3/39, Impact Factor 11.2, 2024, Q1). Effect of acute and chronic inflammatory stimuli on expression of protease-activated receptors 1 and 2 in alveolar macrophages. *J Allergy Clin Immunol* 2003;111:367-373.

27. Paredi P, **Caramori G**, Cramer D, Ward S, Ciaccia A, Papi A, Kharitonov S, Barnes PJ (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Slower rise of exhaled breath temperature in chronic obstructive pulmonary disease. *Eur Respir J* 2003;21:439-443.

28. **Caramori G**, Romagnoli M, Casolari P, Bellettato G, Casoni G, Boschetto P, Chung KF, Barnes PJ, Adcock IM, Ciaccia A, Fabbri LM, Papi A (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. *Thorax* 2003;58:348-351.

29. Braccioni F, Calia N, Castelletti ML, Ravenna F, Pasquini C, Cavallesco G, Grandi E, **Caramori G**, Papi A, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Pulmonary blastoma: case report in an adult. *Monaldi Archiv Chest Dis* 2002;57:318-320.
30. **Caramori G**, Adcock IM (Respiratory System 44/108, Impact Factor 2.8, 2024, Q2). Pharmacology of airway inflammation in asthma and COPD. *Pulm Pharmacol Ther* 2003;16:247-277.
31. **Caramori G**, Papi A (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Oxidants and asthma. *Thorax* 2004;59:170-173.
32. Lim S, **Caramori G**, Tomita K, Jazrawi E, Oates T, Chung KF, Barnes PJ, Adcock IM (Allergy 1/39, Impact Factor 12, 2024, Q1). Differential expression of IL-10 receptor by epithelial cells and alveolar macrophages. *Allergy* 2004;59:505-514.
33. Atzori L, **Caramori G**, Lim S, Jazrawi E, Donnelly L, Adcock I, Barnes PJ, Chung F. (Respiratory System 33/108, Impact Factor 3.1, 2024, Q2). Effect of cigarette smoking on haem-oxygenase expression in alveolar macrophages. *Respir Med* 2004;98:530-535.
34. Di Stefano A, **Caramori G**, Capelli A, Gnemmi I, Ricciardolo FL, Oates T, Balbi B, Lusuardi M, Donner CF, Chung KF, Barnes PJ, Adcock IM (Respiratory System 2/108, Impact Factor 21, 2024, Q1). STAT4 activation in smokers and patients with chronic obstructive pulmonary disease. *Eur Respir J* 2004;24:78-85.
35. Adcock IM, **Caramori G** (Pharmacology and Pharmacy 25/353, Impact Factor 6.9, 2024, Q1). Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next Generation of drugs for severe asthma and COPD?. *Biodrugs* 2004;18:167-180.
36. **Caramori G**, Ito K, Adcock IM. Targeting Th2 cells in asthmatic airways. *Curr Drug Targets Inflamm Allergy* 2004;3:243-255. (continued as *Inflammation & Allergy - Drug Targets*, discontinued in 2015)
37. Adcock IM, **Caramori G**. Chemokine receptor inhibitors as a novel option in the treatment of asthma. *Curr Drug Targets Inflamm Allergy* 2004;3:257-261. (continued as *Inflammation & Allergy - Drug Targets*, discontinued in 2015)
38. Papi A, Casoni G, **Caramori G**, Guzzinati I, Boschetto P, Ravenna F, Calia N, Petruzzelli S, Corbetta L, Cavallesco G, Forini E, Saetta M, Ciaccia A, Fabbri LM. (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). COPD increases the risk of squamous histological subtype in smokers who develop non-small-cell lung cancer. *Thorax* 2004;59:679-681.
39. **Caramori G**, Ito K, Adcock **G** (Pharmacology and Pharmacy publication suspended in 2012). Transcription factors in asthma and COPD. *IDrugs* 2004;7:764-770.
40. Di Stefano A, **Caramori G**, Ricciardolo FLM, Capelli A, Adcock IM, Donner CF (Allergy 7/39, Impact Factor 5.2, 2024, Q1). Cellular and molecular mechanisms in chronic obstructive pulmonary disease: an overview. *Clin Exp Allergy* 2004;34:1156-1167.
41. Chung KF, **Caramori G**, Groneberg DA (Medicine, General and Internal 2/333, Impact Factor 78.5, 2024, Q1). Airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med* 2004;351:1459-1461; author reply 1459-61.
42. **Caramori G**, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Chung KF, Papi A (Pathology 12/90, Impact Factor 4.1, 2024, Q1). Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. *Histopathology* 2004;45:311-319.
43. **Caramori G**, Adcock IM, Ito K (Pharmacology and Pharmacy publication suspended in 2012). Anti-inflammatory inhibitors of I $\kappa$ B kinase in asthma and COPD. *Curr Opin Investig Drugs* 2004;5:1141-1147.
44. **Caramori G**, Pandit A, Papi A (Allergy 18/39, Impact Factor 2.6, 2024, Q2). Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease?. *Curr Opin Allergy Clin Immunol* 2005;5:77-83.

45. Contoli M, **Caramori G**, Mallia P, Johnston S, Papi A (Allergy 7/39, Impact Factor 5.2, 2024, Q1). Mechanisms of respiratory virus-induced asthmatic exacerbations. *Clin Exp Allergy* 2005;35:137-145.
46. Ito K, Ito M, Elliott WM, Cosio M, **Caramori G**, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ (Medicine, General and Internal 2/333, Impact Factor 78.5, 2024, Q1). Decreased histone deacetylase activity in chronic obstructive pulmonary disease: relationship to disease severity. *N Engl J Med* 2005;352:1967-1976.
47. Psarras S, **Caramori G**, Contoli M, Papadopolous N, Papi A (Pharmacology and Pharmacy 162/353, Impact Factor 2.8, 2024, Q2). Oxidants in asthma and chronic obstructive pulmonary disease (COPD). *Curr Pharm Des* 2005;11:2053-2062.
48. **Caramori G**, Bettoncelli G, Tosatto R, Arpinelli F, Visonà G, Invernizzi G, Gerace A, Adcock IM, Ciaccia A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy. *Monaldi Arch Chest Dis* 2005;63:6-12.
49. **Caramori G**, Adcock IM. Anti-inflammatory mechanisms of glucocorticoids targeting granulocytes. *Curr Drug Targets Inflamm Allergy* 2005;4:455-63. (continued as *Inflammation & Allergy - Drug Targets*, discontinued in 2015)
50. **Caramori G**, Fabbri M, Paioli D, Falcone F, Severino C, Felisatti G, Arar O, Adcock IM, Chung KF, Barnes PJ, Ciaccia A, Papi A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Asthma is not a common cause of severe chronic respiratory failure in non-smokers: ALOT study. *Monaldi Arch Chest Dis* 2005;63:84-87.
51. **Caramori G**, Calia N, Pasquini C, Arar O, Ravenna F, Guzzinati I, Boniotti A, Cavazzini L, Ciaccia A, Cavallesco G, Papi A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Ectopic thymoma simulating a pericardial cyst: case report. *Monaldi Arch Chest Dis* 2005;63:230-233.
52. Ricciardolo FLM, **Caramori G**, Ito K, Capelli A, Brun P, Abatangelo G, Papi A, Chung KF, Adcock IM, Barnes PJ, Donner CF, Rossi A, Di Stefano A KF (Allergy 3/39, Impact Factor 11.2, 2024, Q1). Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2005;116:1028-35.
53. Xie S, Issa R, Sukkar MB, Oltmanns U, Bhavsar PK, Papi A, **Caramori G**, Adcock I, Chung KF (Respiratory System 16/108, Impact Factor 5, 2024, Q1). Induction and regulation of matrix metalloproteinase-12 in human airway smooth muscle cells. *Respir Res* 2005;6:148.
54. Varani K\*, **Caramori G\***, Vincenzi F, Adcock IM, Casolari P, Leung E, MacLennan S, Gessi S, Morello S, Barnes PJ, Ito K, Chung KF, Cavallesco G, Azzena G, Papi A\*, Borea PA\* (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care* 2006;173:398-406. \*Both Authors contributed equally to this work.
55. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, **Caramori G**, Fabbri LM, Johnston SL (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care* 2006;173:1114-1121.
56. Adcock IM, **Caramori G**, Ito K (Pharmacology and Pharmacy 193/353, Impact Factor 2.5, 2024, Q3). New insights into the molecular mechanisms of corticosteroids actions. *Curr Drug Targets* 2006;7:649-660.
57. **Caramori G**, Papi A (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Smoking history effect on peripheral lung inflammation and gene transcription in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;174:2-3.
58. **Caramori G**, Ito K, Contoli M, Di Stefano A, Johnston SL, Adcock IM, Papi A (Pharmacology and Pharmacy 112/353, Impact Factor 3.5, 2024, Q2). Molecular

mechanisms of respiratory virus-induced asthma and COPD exacerbations and pneumonia. *Curr Med Chem* 2006;13:2267-90.

59. **Caramori G**, Papi A (Medicine, General and Internal 2/333, Impact Factor 78.5, 2024, Q1). Telithromycin in acute exacerbations of asthma. *N Engl J Med* 2006;355:96; author reply 97-8.

60. **Caramori G**, Adcock IM (Allergy 18/39, Impact Factor 2.6, 2024, Q2). Gene-environment interactions in the development of chronic obstructive pulmonary disease. *Curr Opin Allergy Clin Immunol* 2006;6:323-338.

61. **Caramori G**, Ito K, Papi A, Adcock IM. Interactions between long-acting  $\beta$ 2-agonists and glucocorticoids. *Drug Discovery Today: Therapeutic Strategies* 2006;3:261-268. (discontinued in 2014)

62. Mallia P, Contoli M, **Caramori G**, Johnston SL, Papi A (Pharmacology and Pharmacy 162/353, Impact Factor 2.8, 2024, Q2). Exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Focus on virus induced exacerbations. *Curr Pharm Des* 2007;13:73-97.

63. Ito K, **Caramori G**, Adcock IM. (Pharmacology and Pharmacy 92/353, Impact Factor 3.8, 2024, Q2). Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. *J Pharmacol Exp Ther* 2007;321:1-8.

64. Romagnoli M, **Caramori G**, Braccioni F, Ravenna F, Barreiro E, Siafakas NM, Vignola AM, Chanez P, Fabbri LM, Papi A and the ENFUMOSA Study Group ((Allergy 7/39, Impact Factor 5.2, 2024, Q1). Near-fatal asthma phenotype in the ENFUMOSA Cohort. *Clin Exp Allergy* 2007;37:552-557.

65. **Caramori G**, Bettoncelli G, Carone M, Tosatto R, Di Blasi P, Pieretto A, Invernizzi G, Novelletto BF, Ciaccia A, Adcock IM, Papi A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Degree of control of physician-diagnosed asthma and COPD in Italy. *Monaldi Arch Chest Dis* 2007;67:15-22.

67 Contoli M, **Caramori G**, Mallia P, Papi A, Johnston SL. A human rhinovirus model of chronic obstructive pulmonary disease exacerbations. *Contrib Microbiol* 2007;14:101-112.

68 Papi A, Contoli M, **Caramori G**, Mallia P, Johnston SL (Pharmacology and Pharmacy 75/353, Impact Factor 4.2, 2024, Q1). Models of infection and exacerbations in COPD. *Curr Opin Pharmacol* 2007;7:259-265. Erratum in: *Curr Opin Pharmacol* 2007;7:451. Gaetano, **Caramori** [corrected to **Caramori**, Gaetano].

69. **Caramori G**, Papi A (Respiratory System 47/108, Impact Factor 2.7, 2024, Q2). Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer. *Expert Rev Respir Med* 2007;1:171-175.

70. Potena A, **Caramori G**, Casolari P, Contoli M, Johnston SL, Papi A (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Pathophysiology of viral-induced exacerbations of COPD. *Int J Chronic Obstruct* 2007;2:477-483.

71. **Caramori G**, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A (Public, Environmental and Occupational Health 133/421, Impact Factor 2.7, 2024, Q2). New drugs targeting Th2 lymphocytes in asthma. *J Occup Med Tox* 2008;3(suppl 1):S6-S35.

72. Bartlett NW, Walton RP, Edwards MR, Aniscenko J, **Caramori G**, Jourdan P, Burnet J, Tuthill TJ, Pedrick MS, Hurlle MJ, Plumpton C, Sharp NA, Bussell JN, Swallow DM, Schwarze1 J, Guy B, Almond JW, Papi A, Killington RA, Rowlands DJ, Blair ED, Clarke NJ, and Johnston SL (Medicine, Research and Experimental 1/195, Impact Factor 50, 2024, Q1). Rhinovirus-induced disease and exacerbation of allergic inflammation in mouse models of rhinovirus infection and rhinovirus-induced asthma exacerbation. *Nat Med* 2008;14:199-204.

73. **Caramori G**, Ito K, Jazrawi E, Casolari P, Chung KF, Barnes PJ, Adcock IM, Papi A. Recent thymic emigrants do not account for the increased number of T-cells seen in the

- lungs of stable chronic obstructive pulmonary disease. *The Open Pathol J* 2008;2:102-105. (discontinued in 2014)
74. Papi A, Contoli M, Gasparini P, Bristol L, Edwards MR, Chicca M, Leis M, Ciaccia A, **Caramori G**, Johnston SL, Pinamonti S (*Biochemistry and Molecular Biology* 118/320, Impact Factor 3.9, 2024, Q2). Role of xanthine-oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. *J Biol Chem* 2008;283:28595-28606.
75. Adcock IM, **Caramori G**, Chung KF (*Medicine, General and Internal* 1/333, Impact Factor 88.5, 2024, Q1). New targets for drug development in asthma. *Lancet* 2008;372:1073-1087.
76. Marwick JA\*, **Caramori G**, Stevenson CS, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham P, Papi A (*Respiratory System* 4/108, Impact Factor 19.4, 2024, Q1). Inhibition of PI3K $\delta$  restores glucocorticoid function in smoking-induced airway inflammation in mice. *Am J Respir Crit Care Med* 2009;179:542-548. \*Selected for the cover page of the print issue.
77. **Caramori G**, Adcock IM, Papi A (*Medicine, General and Internal* 195/333, Impact Factor 0.8, 2024, Q3). Clinical definition of COPD exacerbations and classification of their severity. *South Med J* 2009;102:277-282. CME article for the Southern Medical Association.
78. **Caramori G**, Oates T, Nicholson AG, Casolari P, Ito K, Barnes PJ, Papi A Adcock IM, Chung KF (*Pathology* 12/90, Impact Factor 4.1, 2024, Q1). Activation of NF- $\kappa$ B transcription factor in asthma death. *Histopathology* 2009;54:507-509.
79. Papi A, **Caramori G**, Adcock IM, Barnes PJ (*Respiratory System* 7/108, Impact Factor 8.6, 2024, Q1). Rescue treatment in asthma. More than as-needed bronchodilation. *Chest* 2009;135:1628-1633.
80. Di Stefano A\*, **Caramori G\***, Gnemmi I, Contoli M, Vicari C, Capelli A, Magno F, D'Anna SE, Zanini A, Brun P, Casolari P, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B (*Immunology* 73/184, Impact Factor 3.8, 2024, Q2). T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients. *Clin Exp Immunol* 2009;157:316-324. \*Both Authors contributed equally to this work.
81. **Caramori G**, Contoli M, Papi A. Attuali progressi nel trattamento dell'asma bronchiale nell'adulto. *Rec Progr Med* 2009;100:171-179.
82. Chung KF, **Caramori G**, Adcock IM (*Pharmacology and Pharmacy System* 173/353, Impact Factor 2.7, 2024, Q2). Inhaled corticosteroids as combination therapy with  $\beta$ -adrenergic agonists in airways disease: present and future. *Eur J Clin Pharmacol* 2009;65:853-871.
83. **Caramori G**, Casolari P, Di Gregorio C, Saetta M, Baraldo S, Boschetto P, Ito K, Fabbri LM, Barnes PJ, Adcock IM, Cavallese G, Chung KF, Papi A (*Pathology* 12/90, Impact Factor 4.1, 2024, Q1). MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. *Histopathology* 2009; 55:321-331.
84. Di Stefano A\*, **Caramori G\***, Gnemmi I, Contoli M, Bristol L, Capelli A, Fabio LM Ricciardolo FLM, Magno F, D'Anna SE, Zanini A, Carbone M, Sabatini F, Usai C, Brun P, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B (*Respiratory System* 8/108, Impact Factor 7.7, 2024, Q1). Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. *Thorax* 2009; 64:968-975. \*Both Authors contributed equally to this work.
85. Contoli M, Marku B, Conti V, Saturni S, **Caramori G**, Papi A. Viral infections in exacerbations of asthma and chronic obstructive pulmonary disease. *Minerva Med* 2009;100:467-478.

86. Varani K\*, **Caramori G\***, Vincenzi F, Tosi A, Barcwizk A, Contoli M, Casolari P, Triggiani M, Hansel T, Leung E, MacLennan S, Barnes PJ, Chung KF, Adcock IM, Papi A\*, Borea PA\* (Biology 17/108, Impact Factor 4.2, 2024 Q1). Oxidative/nitrosative stress selectively alters A2b adenosine receptors in chronic obstructive pulmonary disease. *FASEB J* 2010;24:1192-1204. \*Both Authours contributed equally to this work.
87. Contoli M, Saetta M, Marku B, Casolari P, Baraldo S, Marwick JA, Turato G, Romagnoli M, **Caramori G**, Fabbri LM, Papi A KF (Allergy 3/39, Impact Factor 11.2, 2024, Q1). Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. *J Allergy Clin Immunol* 2010;125:830-837.
88. Marwick JA, **Caramori G**, Mazzoni F, Kirkham P, Casolari P, Adcock IM, Chung KF, Papi A (Allergy 3/39, Impact Factor 11.2, 2024, Q1). A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2010;125:1146-1153.
89. Tomita K, **Caramori G**, Ito K, Lim S, Sano H, Tohda Y, Adcock IM, Barnes PJ. Telomere shortening in alveolar macrophages of smokers and COPD patients. *The Open Pathol J* 2010;4:23-29. (publication discontinued in 2014).
90. **Caramori G**, Rigolin GM, Mazzoni F, Leprotti S, Campione P, Papi A (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Circulating endothelial stem cells are not decreased in pulmonary emphysema or chronic obstructive pulmonary disease *Thorax* 2010; 65:554-555.
91. Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Keadze T, **Caramori G**, Zhu J, Edbrooke MR, Stanciu LA, Kon OM, Papi A, Jeffery PK, Edwards MR, Johnston SL (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Rhinovirus induces MUC5AC in a human infection model and in vitro via NF- $\kappa$ B and EGFR pathways. *Eur Respir J* 2010;36:1425-35.
92. **Caramori G**, Casolari P, Cavallesco GN, Giuffrè S, Adcock I, Papi A (Biochemistry and Molecular Biology 191/320, Impact Factor 2.8, 2024, Q3). Mechanisms involved in lung cancer development in COPD. *Int J Biochem Cell Biol* 2011;43:1030-1044.
93. Adcock IM, Marwick J, Casolari P, Contoli M, Chung KF, Kirkham P, Papi A, **Caramori G** (Pharmacology and Pharmacy 162/353, Impact Factor 2.8, 2024, Q2). Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD). *Curr Pharm Des* 2010;16:3554-3573.
94. **Caramori G**, Casolari P, Giuffrè S, Barczyk A, Adcock I, Papi A. COPD pathology in the small airways. *Panminerva Med* 2011;53:51-70.
95. Adcock IM, **Caramori G**, Barnes PJ (Respiratory System 25/108, Impact Factor 3.8, 2024, Q1). Chronic obstructive pulmonary disease and lung cancer: new molecular insights. *Respiration* 2011;81:265-284.
96. **Caramori G**, Adcock IM, Casolari P, Ito K, Jazrawi E, Tsaprouni L, Villetti G, Civelli M, Carnini C, Chung KF, Barnes PJ, Papi A (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. *Thorax* 2011;66:521-527.
97. D'Anna SE, Asnaghi R, **Caramori G**, Appendini L, Rizzo M, Cavallaro C, Marino G, Cappello F, Balbi B, Di Stefano A (Respiratory System 25/108, Impact Factor 3.8, 2024, Q1). High-resolution computed tomography quantitation of emphysema is correlated with selected lung function values in stable COPD. *Respiration* 2012;83:383-390.
98. **Caramori G**, Lasagna L, Casalini AG, Adcock IM, Casolari P, Contoli M, Tafuro F, Padovani A, Chung KF, Barnes PJ, Papi A, Rindi G, Bertorelli G (Multidisciplinary Sciences 44/136, Impact Factor 2.6, 2024, Q2). Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. *PLoS One* 2011;6:e22637.

99. Cazzuffi R, Calia N, Ravenna F, Pasquini C, Saturni S, Cavallesco GN, Quarantotto F, Rinaldi R, Cogo A, **Caramori G**, Papi A (Medicine, General and Internal 208/333, Impact Factor 0.7, 2024, Q3). Primary pulmonary epithelioid hemangioendothelioma: a rare cause of PET-negative pulmonary nodules. *Case Reports Med* 2011;2011:262674.
100. Kirkham PA\*, **Caramori G\***, Casolari P, Papi A, Edwards M, Shamji B, Triantaphyllopoulos K, Hussain F, Pinart M, Khan Y, Heinemann L, Stevens L, Yeadon M, Barnes PJ, Chung KF, Adcock IM (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2011; 184:796-802. \*Both Authors contributed equally to this work.
101. Cappello F, **Caramori G**, Campanella C, Vicari C, Gnemmi I, Zanini A, Spanevello A, Capelli A, Rocca GL, Anzalone R, Bucchieri F, D'Anna SE, Ricciardolo FL, Brun P, Balbi B, Carone M, Zummo G, Macario EC, Macario AJ, Stefano AD (Multidisciplinary Sciences 44/136, Impact Factor 2.6, 2024, Q2). Convergent sets of data from in vitro and in vivo methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis. *PLoS One* 2011;6:e28200.
102. Ravenna F, Saturni S, Casalini A, Pilato FP, Pasquini C, **Caramori G**, Papi A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Bronchial glomus tumor mimicking a COPD exacerbation. *Mon Arch Chest Dis* 2011;75:194-198.
103. **Caramori G**, Casolari P, Garofano E, Mazzoni F, Marchi I, Contoli M, Papi A. Ruolo delle cellule staminali nella patogenesi della broncopneumopatia cronica ostruttiva e dell'enfisema polmonare. *Rec Prog Med* 2012;103:31-40.
104. Feo CV, **Caramori G**, Conti V, Calia N, Guzzinati I, Ravenna F, Pasquini C, De Troia A, Liboni A, Papi A (Surgery 230/314, Impact Factor 0.9, 2024, Q3). Esophageal achalasia with recurrent aspiration pneumoniae treated by laparoscopic heller myotomy. *Am Surg* 2012;78:168-70.
105. Tomita K, **Caramori G**, Ito K, Sano H, Lim S, Oates T, Cosio B, Chung KF, Tohda Y, Barnes PJ, Adcock IM (Immunology 63/184, Impact Factor 4.1, 2024, Q2). STAT6 expression in T cells, alveolar macrophages, and bronchial biopsies of normal and asthmatic subjects. *J Inflamm (Lond)* 2012;9:1-10.
106. Adcock IM, **Caramori G**, Kirkham PA (Pharmacology and Pharmacy 75/353, Impact Factor 4.2, 2024, Q1). Strategies for improving the efficacy and therapeutic ratio of glucocorticoids. *Curr Opin Pharmacol* 2012;12:246-251.
107. Marangoni E, Alvisi V, Ragazzi R, Mojoli F, Alvisi R, **Caramori G**, Astolfi L, Volta CA (Anesthesiology 18/68, Impact Factor 2.8, 2024, Q1). Respiratory mechanics at different PEEP level during general anesthesia in the elderly: a pilot study. *Minerva Anesthesiol* 2012;78:1205-1214.
108. Baraldo S, Contoli M, Bazzan E, Turato G, Padovani A, Marku B, Calabrese F, **Caramori G**, Ballarin A, Sniijders D, Barbato A, Saetta M, Papi (Allergy 3/39, Impact Factor 11.2, 2024, Q1). Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma. *J Allergy Clin Immunol* 2012;130:1307-1014.
109. **Caramori G**, Papadopoulos N, Contoli M, Marku B, Forini G, Pauletti A, Johnston SL, Papi A (Respiratory System 18/108, Impact Factor 4.5, 2024, Q1). Asthma a chronic infectious disease?. *Clin Chest Med* 2012;33:473-484.
110. Bartlett NW, Slater L, Glanville N, Haas JJ, **Caramori G**, Casolari P, Clarke DL, Message SD, Aniscenko J, Keadze T, Zhu J, Mallia P, Mizgerd JP, Belvisi M, Papi A, Kotenko SV, Johnston SL, Edwards MR (Medicine, Research and Experimental 21/195, Impact Factor 8.3, 2024, Q1). Defining critical roles for NF- $\kappa$ B p65 and type I interferon in innate immunity to rhinovirus. *EMBO Mol Med* 2012;4:1244-1260.

111. Durham AL, McLaren A, Hayes BP, **Caramori G**, Clayton CL, Barnes PJ, Chung KF, Adcock IM (Biology 17/108, Impact Factor 4.2, 2024 Q1). Regulation of Wnt4 in chronic obstructive pulmonary disease. *FASEB J* 2013;27:2367-2381.
112. **Caramori G**, Casolari P, Adcock I. Role of transcription factors in the pathogenesis of asthma and COPD. *Cell Commun Adhes* 2013;20:21-40. (Journal discontinued in 2018)
113. **Caramori G**, Artioli D, Ferrara G, Cazzuffi R, Pasquini C, Libanore M, Guardigni V, Guzzinati I, Contoli M, Rossi R, Rinaldi R, Contini C, Papi A (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review. *Monaldi Arch Chest Dis* 2013;79:44-8.
114. Papi A, Contoli M, Adcock IM, Bellettato C, Padovani A, Casolari P, Stanciu LA, Barnes PJ, Johnston SL, Ito K, **Caramori G** (Allergy 3/39, Impact Factor 11.2, 2024, Q1). Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor  $\kappa$ B and c-Jun N-terminal kinase activation. *J Allergy Clin Immunol.* 2013;132:1075-1085.
115. **Caramori G**, Paredi P (Respiratory System 25/108, Impact Factor 3.8, 2024, Q1). Global lung function standardisation: finally making our dream a reality? *Respiration* 2013;86:179-180.
116. **Caramori G**, Di Stefano A, Casolari P, Kirkham PA, Padovani A, Chung KF, Papi A, Adcock IM (Pharmacology and Pharmacy 112/353, Impact Factor 3.5, 2024, Q2). Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease. *Curr Med Chem* 2013;20:4317-4349.
117. Price LC, **Caramori G**, Perros F, Meng C, Gambaryan N, Dorfmuller P, Montani D, Casolari P, Zhu J, Dimopoulos K, Shao D, Girerd B, Mumby S, Proudfoot A, Griffiths M, Papi A, Humbert M, Adcock IM, Wort SJ (Multidisciplinary Sciences 44/136, Impact Factor 2.6, 2024, Q2). Nuclear factor  $\kappa$ -B is activated in the pulmonary vessels of patients with end-Stage idiopathic pulmonary arterial hypertension. *PLoS One* 2013;8:e75415.
118. Ravenna F, Conti V, Salviato E, Marangoni E, Verri M, Paolazzi M, Galeotti R, **Caramori G** (Medicine, General and Internal 185/333, Impact Factor 0.9, 2024, Q3). Endobronchial metastases of renal cell carcinoma: a complex multidisciplinary treatment. *Journal of Medical Cases* 2013;4:644-647.
119. Caminati M, Bettoncelli G, Sandra Magnoni M, Rizzi A, Testi R, Passalacqua G, De Marco R, **Caramori G**, Senna G (Allergy 29/39, Impact Factor 1.3, 2024, Q3). The level of control of mild asthma in general practice: an observational community-based study. *J Asthma* 2014;51:91-96.
120. Di Stefano A, **Caramori G**, Barczyk A, Vicari C, Brun P, Zanini A, Cappello F, Garofano E, Padovani A, Contoli M, Casolari P, Durham AL, Chung KF, Barnes PJ, Papi A, Adcock I, Balbi B (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD. *Thorax* 2014;69:516-524.
121. Jayaraman A, Jackson DJ, Message SD, Pearson RM, Aniscenko J, **Caramori G**, Mallia P, Papi A, Shamji B, Edwards M, Westwick J, Hansel T, Stanciu LA, Johnston SL, Bartlett NW (Immunology 21/184, Impact Factor 7.6, 2024, Q1). IL-15 complexes induce NK- and T-cell responses independent of type I IFN signaling during rhinovirus infection. *Mucosal Immunol* 2014;7:1151-1164.
122. **Caramori G**, Chung KF, Adcock IM (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD. *Int J Chron Obstruct* 2014;9:249-256. eCollection 2014.
123. Telcian AG, Zdrengeha MT, **Caramori G**, Laza-Stanca V, Message SD, Kebabze T, Kon OM, Groh V, Papi A, Johnston SL, Mallia P, Stanciu LA PJ (Respiratory System 7/108, Impact Factor 8.6, 2024, Q1). Soluble MHC class I-related chain B molecules are

increased and correlate with clinical outcomes during rhinovirus infection in healthy subjects. *Chest* 2014; 146:32-40.

124. Kirkham PA, Whiteman M, Winyard PG, **Caramori G**, Gordon F, Ford PA, Barnes PJ, Adcock IM, Chung KF (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. *Eur Respir J* 2014;43:1504-1506.

125. **Caramori G**, Chung KF, Adcock IM (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Cytokine inhibition in the treatment of COPD. *Int J Chron Obstruct* 2014;9:397-412. eCollection 2014.

126. Gnatiuc L, **Caramori G** (Respiratory System 2/108, Impact Factor 21, 2024, Q1). COPD in nonsmokers: the biomass hypothesis - to be or not to be? *Eur Respir J* 2014;44:8-10.

127. Shao D, Perros F, **Caramori G**, Meng C, Dormuller P, Chou PC, Church C, Papi A, Casolari P, Welsh D, Peacock A, Humbert M, Adcock IM, Wort SJ (Biochemistry and Molecular Biology 242/320, Impact Factor 2.2, 2024, Q4). Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. *Biochem Biophys Res Commun* 2014;451:8-14.

128. Barczyk A, Pierzchała E, **Caramori G**, Sozańska E. Increased expression of CCL14/MIP-1 $\alpha$  in CD8<sup>+</sup> cells and CD4<sup>+</sup> cells in sarcoidosis. *Int J Immunopathol Pharmacol.* 2014;27:185-193.

129. Barczyk A, Pierzchała W, **Caramori G**, Wiaderkiewicz R, Kaminski M, Barnes PJ, Adcock IM (Immunology 63/184, Impact Factor 4.1, 2024, Q2). Decreased percentage of CD4(+)Foxp3(+)TGF- $\beta$ (+) and increased percentage of CD4(+)IL-17(+) cells in bronchoalveolar lavage of asthmatics. *J Inflamm (Lond)* 2014;11:22-31.

130. **Caramori G**, Kirkham P, Barczyk A, Di Stefano A, Adcock I (Multidisciplinary Sciences 19/136, Impact Factor 4.8, 2024, Q1). Molecular pathogenesis of cigarette smoking-induced stable COPD. *Ann N Y Acad Sci* 2015;1340:55-64.

131. Vallese D, Ricciardolo FL, Gnemmi I, Casolari P, Brun P, Sorbello V, Capelli A, Cappello F, Cavallesco GN, Papi A, Chung KF, Balbi B, Adcock IM, **Caramori G**, Di Stefano A (Respiratory System 25/108, Impact Factor 3.8, 2024, Q1). Phospho-p38 MAPK Expression in COPD patients and asthmatics and in challenged bronchial epithelium. *Respiration* 2015;89:329-342.

132. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, Stanciu LA, Gnesini G, Pastore A, Spanevello A, Morelli P, Johnston SL, **Caramori G**, Papi A (Allergy 1/39, Impact Factor 12, 2024, Q1). Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. *Allergy* 2015;70:910-920.

133. Ngkelo A, Hoffmann RF, Durham AL, Marwick JA, Brandenburg SM, de Bruin HG, Jonker MR, Rossios C, Tsitsiou E, **Caramori G**, Contoli M, Casolari P, Monaco F, Andò F, Speciale G, Kilty I, Chung KF, Papi A, Lindsay MA, Ten Hacken NH, van den Berge M, Timens W, Barnes PJ, van Oosterhout AJ, Adcock IM, Kirkham PA, Heijink IH (Respiratory System 26/108, Impact Factor 3.5, 2024, Q1). Glycogen synthase kinase-3 $\beta$  modulation of glucocorticoid responsiveness in COPD. *Am J Physiol Lung Cell Mol Physiol* 2015;309:L1112-L1123.

134. **Caramori G**, Chung KF, Barnes PJ (Medicine, General and Internal 2/333, Impact Factor 78.5, 2024, Q1). Allergen responses modified by a GATA3 DNzyme. *N Engl J Med* 2015;373:1176-1177.

135. Magnoni MS, Caminati M, Senna G, Arpinelli F, Rizzi A, Dama AR, Schiappoli M, Bettoncelli G, **Caramori G**. Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy. *Clin Mol Allergy* 2015;13:26-30.
136. Durham AL, **Caramori G**, Chung KF, Adcock IM (Medicine, General and Internal 30/333, Impact Factor 5.9, 2024, Q1). Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. *Transl Res* 2016;167:192-203.
137. Conti C, Montero-Fernandez A, Borg E, Osadolor T, Viola P, De Lauretis A, Stock CJ, Bonifazi M, Bonini M, **Caramori G**, Lindahl G, Blasi FB, Nicholson AG, Wells AU, Sestini P, Renzoni E (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Mucins MUC5B and MUC5AC in distal airways and honeycomb spaces: comparison among idiopathic pulmonary fibrosis/usual interstitial pneumonia, fibrotic nonspecific interstitial pneumonitis, and control lungs. *Am J Respir Crit Care Med* 2016;193:462-464.
138. **Caramori G**, Casolari P, Barczyk A, Durham AL, Di Stefano A, Adcock I (Pathology 43/90, Impact Factor 9.2, 2024, Q1). COPD immunopathology. *Semin Immunopathol* 2016;38:497-515.
139. Fabbian F, De Giorgi A, Manfredini F, Lamberti N, Forcellini S, Storari A, Gallerani M, **Caramori G**, Manfredini R (Urology and Nephrology 72/134, Impact Factor 1.9, 2024, Q3). Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study. *Int Urol Nephrol* 2016;48:1121-1127.
140. Poletti D, Iannini V, Casolari P, Contoli M, Papi A, Kirkham P, Hansel TT, Chung KF, Barnes PJ, Pastore A, Pelucchi S, Adcock IM, **Caramori G** (Immunology 63/184, Impact Factor 4.1, 2024, Q2). Nasal inflammation and its response to local glucocorticoid regular treatment in patients with persistent non-allergic rhinitis: a pilot study. *J Inflamm (Lond)* 2016;13:26.
141. Spadaro S, **Caramori G**, Rizzuto C, Mojoli F, Zani G, Ragazzi R, Valpiani G, Della Corte F, Marangoni E, Volta CA (Anesthesiology 98/68, Impact Factor 3.8, 2024, Q1). Expiratory flow limitation as a risk factor for pulmonary complications after major abdominal surgery. *Anesth Analg* 2017;124:524-530.
141. Arpinelli F, **Caramori G**, Magnoni MS. [Risk of pneumonia during long term regular treatment of stable COPD with inhaled glucocorticoids: a systematic review.][Article in Italian] *Recenti Prog Med* 2017;108:175-182.
142. Di Stefano A, Ricciardolo FLM, **Caramori G**, Adcock IM, Chung KF, Barnes PJ, Brun P, Leonardi A, Andò F, Vallese D, Gnemmi I, Righi L, Cappello F, Balbi B (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression. *Eur Respir J* 2017 May 23;49(5). pii: 1602006. doi: 10.1183/13993003.02006-2016. Print 2017 May.
143. Spadaro S, Kozhevnikova I, Casolari P, Ruggeri P, Bellini T, Ragazzi R, Barbieri F, Marangoni E, **Caramori G**, Volta CA (Respiratory System 30/108, Impact Factor 3.4, 2024, Q2). Lower airways inflammation in patients with ARDS measured using endotracheal aspirates: a pilot study. *BMJ Open Respir Res* 2017 Sep 4;4(1):e000222. doi: 10.1136/bmjresp-2017-000222. eCollection 2017.
144. Contoli M, Pauletti A, Rossi MR, Spanevello A, Casolari P, Marcellini A, Forini G, Gnesini G, Marku B, Barnes N, Rizzi A, Curradi G, **Caramori G**, Morelli P, Papi A (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. *Eur Respir J*. 2017 Oct 5;50(4). pii: 1700451. doi: 10.1183/13993003.00451-2017. Print 2017 Oct.
145. **Caramori G**, Ruggeri P, Casolari P, Chung KF, Girbino G, Adcock IM (Respiratory System 47/108, Impact Factor 2.7, 2024, Q2). Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. *Expert Rev Respir Med* 2017;11:955-967.

146. Ruggeri P, Lo Bello F, Nucera F, Gaeta M, Monaco F, **Caramori G**, Girbino G (Respiratory System 90/108, Impact Factor 0.8, 2024, Q4). Hereditary hyperhomocysteinemia associated with nephrotic syndrome complicated by artery thrombosis and chronic thromboembolic pulmonary hypertension: A case report. *Monaldi Arch Chest Dis* 2017;87:880. doi: 10.4081/monaldi.2017.880.
147. Maniscalco M, Paris D, Melck DJ, Molino A, Carone M, Ruggeri P, **Caramori G**, Motta A (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Differential diagnosis between newly diagnosed asthma and COPD using exhaled breath condensate metabolomics: a pilot study. *Eur Respir J* 2018;51. pii: 1701825. doi: 10.1183/13993003.01825-2017. Print 2018 Mar. No abstract available.
148. Di Stefano A, Sangiorgi C, Gnemmi I, Casolari P, Brun P, Ricciardolo FL, Contoli M, Papi A, Maniscalco P, Ruggeri P, Girbino G, Cappello F, Pavlides S, Guo Y, Chung KF, Barnes PJ, Adcock IM, Balbi B, **Caramori G** PJ (Respiratory System 7/108, Impact Factor 8.6, 2024, Q1). TGF- $\beta$  signalling pathways in different compartments of the lower airways of stable COPD patients. *Chest* 2018;153:851-862.
149. **Caramori G**, Ruggeri P, Di Stefano A, Mumby S, Girbino G, Adcock IM, Kirkham P PJ (Respiratory System 7/108, Impact Factor 8.6, 2024, Q1). Autoimmunity and COPD: Clinical Implications. *Chest* 2018;153:1424-1431.
150. Proietto A, Nucera F, **Caramori G** (Medicine, General and Internal 195/333, Impact Factor 0.8, 2024, Q3). Commentary on "Major complications associated with conventional transbronchial needle aspiration". *South Med J* 2018;111:572-573. doi: 10.14423/SMJ.0000000000000859.
151. Adcock IM, Mumby S, **Caramori G** (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Breaking news: DNA damage and repair pathways in COPD and implications for pathogenesis and treatment. *Eur Respir J* 2018 Oct 4;52(4). pii: 1801718. doi: 10.1183/13993003.01718-2018. Print 2018 Oct.
152. Ricciardi L, Col JD, Casolari P, Memoli D, Conti V, Vatrella A, Vonakis BM, Papi A, **Caramori G**, Stellato C (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients. *Int J Chron Obstruct Pulmon Dis* 2018;13:3173-3190.
153. Coppolino I, Ruggeri P, Nucera F, Cannavò MF, Adcock I, Girbino G, **Caramori G** (Respiratory System 61/108, Impact Factor 2.1, 2024, Q3). Role of Stem Cells in the Pathogenesis of Chronic Obstructive Pulmonary Disease and Pulmonary Emphysema. *COPD* 2018;15:536-556. doi: 10.1080/15412555.2018.1536116.
154. Spadaro S, Park M, Turrini C, Tunstall T, Thwaites R, Mauri T, Ragazzi R, Ruggeri P, Hansel TT, **Caramori G**, Volta CA (Immunology 63/184, Impact Factor 4.1, 2024, Q2). Biomarkers for acute respiratory distress syndrome and prospects for personalised medicine. *J Inflamm (Lond)* 2019;16:1. doi: 10.1186/s12950-018-0202-y. eCollection 2019.
155. Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, **Caramori G**, Cari L, Chung KF, Diamant Z, Eguiluz-Gracia I, Knol E, Kolios A, Levi-Schaffer F, Nocentini G, Palomares O, Puzzovio PG, Redegeld F, Van Esch B, Stellato C (Allergy 1/39, Impact Factor 12, 2024, Q1). Comparing biologicals and small molecule drug therapies for chronic respiratory diseases. *Allergy* 2019;74:432-448. doi: 10.1111/all.13642. Epub 2019 Jan 8.
156. Ruggeri P, **Caramori G** (Respiratory System 4/108, Impact Factor 19.4, 2024, Q1). Functional role of inflammasome activation in a subset of obese nonsmoking patients with severe asthma. *Am J Respir Crit Care Med* 2019;199:1045-1047.
157. Sikora-Skrabaka M, Skrabaka D, Ruggeri P, **Caramori G**, Skoczyński S, Barczyk A ((Respiratory System 68/108, Impact Factor 1.9, 2024, Q3). D-dimer value in the diagnosis of pulmonary embolism-may it exclude only? *J Thorac Dis* 2019;11:664-672.

158. **Caramori G**, Ruggeri P, Mumby S, Ieni A, Lo Bello F, Chimankar V, Donovan C, Andò F, Nucera F, Coppolino I, Tuccari G, Hansbro PM, Adcock IM (Pharmacology and Pharmacy 68/353, Impact Factor 4.4, 2024, Q1). Molecular links between COPD and lung cancer: new targets for drug discovery? *Expert Opin Ther Targets* 2019;23:539-553.
159. **Caramori G**, Ruggeri P, Arpinelli F, Salvi L, Girbino G (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature. *Int J Chron Obstruct Pulmon Dis* 2019;14:1085-1097. eCollection 2019.
160. Starkey MR, Plank MW, Casolari P, Papi A, Pavlidis S, Guo Y, Cameron GJM, Haw TJ, Tam A, Obiedat M, Donovan C, Hansbro NG, Nguyen DH, Nair PM, Kim RY, Horvat JC, Kaiko GE, Durum SK, Wark PA, Sin DD, **Caramori G**, Adcock IM, Foster PS, Hansbro PM (Respiratory System 2/108, Impact Factor 21, 2024, Q1). IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis. *Eur Respir J* 2019;54. pii: 1800174. doi: 10.1183/13993003.00174-2018. Print 2019 Jul.
161. **Caramori G**, Coppolino I, Cannavò MF, Nucera F, Proietto A, Mumby S, Ruggeri P, Adcock IM (Pharmacology and Pharmacy 75/353, Impact Factor 4.2, 2024, Q1). Transcription inhibitors and inflammatory cell activity. *Curr Opin Pharmacol* 2019;46:82-89.
162. Ruggeri P, **Caramori G** (Respiratory System 26/108, Impact Factor 3.5, 2024, Q1). Interferonopathy: a potential link between innate immunity and autoimmunity in the pathogenesis of COPD. *Am J Physiol Lung Cell Mol Physiol* 2019;317:L888-L890. doi: 10.1152/ajplung.00439.2019. Epub 2019 Oct 30
163. Balbi B, Sangiorgi C, Gnemmi I, Ferrarotti I, Vallese D, Paracchini E, Delle Donne L, Corda L, Baderna P, Corsico A, Carone M, Brun P, Cappello F, Ricciardolo FL, Ruggeri P, Mumby S, Adcock IM, **Caramori G**, Di Stefano A (Respiratory System 34/108, Impact Factor 3.1, 2024, Q2). Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2019;14:1879-1893. doi: 10.2147/COPD.S207203. eCollection 2019
164. Lo Bello F, Ieni A, Hansbro PM, Ruggeri P, Di Stefano A, Nucera F, Coppolino I, Monaco F, Tuccari G, Adcock IM, **Caramori G** (Respiratory System 47/108, Impact Factor 2.7, 2024, Q2). Role of the mucins in pathogenesis of COPD: implications for therapy. *Expert Rev Respir Med* 2020;14:465-483.
165. Ruggeri P, Lo Monaco L, Musumeci O, Tavilla G, Gaeta M, **Caramori G**, Toscano A (Clinical Neurology 154/286, Impact Factor 2.4, 2024, Q3). Ultrasound assessment of diaphragm function in patients with late-onset Pompe disease. *Neurol Sci* 2020;41:2175-2184.
166. D'Anna SE, Maniscalco M, Carriero V, Gnemmi I, **Caramori G**, Nucera F, Righi L, Brun P, Balbi B, Adcock IM, Stella MG, Ricciardolo FLM, Di Stefano A (Medicine, General and Internal 65/333, Impact Factor 2.9, 2024, Q1). Evaluation of innate immune mediators related to respiratory viruses in the lung of stable COPD patients. *J Clin Med* 2020;9:1807. doi: 10.3390/jcm9061807.
167. Cipolla G, Relo R, Pasciuta E, Catalano D, Lo Bello F, Coppolino I, Ruggeri P, Proietto A, Buccafusca M, Cutroneo PM, Trifirò G, **Caramori G** (System 90/108, Impact Factor 0.8, 2024, Q4). A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT. *Monaldi Arch Chest Dis* 2020;90(3). doi: 10.4081/monaldi.2020.1352.
168. Scichilone N, Barnes PJ, Battaglia S, Benfante A, Brown R, Canonica GW, **Caramori G**, Cazzola M, Centanni S, Cianferoni A, Corsico A, De Carlo G, Di Marco F, Gaga M, Hawrylowicz C, Heffler E, Matera MG, Matucci A, Paggiaro P, Papi A, Popov T, Rogliani P, Santus P, Solidoro P, Toghias A, Boulet LP (Medicine, General and Internal 65/333, Impact Factor 2.9, 2024, Q1). The hidden burden of severe asthma: from patient

- perspective to new opportunities for clinicians. *J Clin Med* 2020;9:E2397. doi: 10.3390/jcm9082397.
169. Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, **Caramori G**, Trifirò G (Pharmacology and Pharmacy 93/353, Impact Factor 3.8, 2024, Q2). Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. *Drug Saf* 2020;43:691-698.
170. Isgrò V, Sultana J, Fontana A, Ientile V, Alecci U, Scoglio R, Magliozzo F, Scodotto S, **Caramori G**, Cazzola M, Trifirò G (Respiratory System 22/108, Impact Factor 4, 2024, Q1). Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. *ERJ Open Res* 2020;6:00279-2020. eCollection 2020 Jul.
171. Stock CJ, Conti C, Montero-Fernandez Á, **Caramori G**, Molyneaux PL, George PM, Kokosi M, Kouranos V, Maher TM, Chua F, Rice A, Denton CP, Nicholson AG, Wells A, Sestini P, Renzoni EA (Respiratory System 8/108, Impact Factor 7.7, 2024, Q1). Interaction between the promoter *MUC5B* polymorphism and mucin expression: is there a difference according to ILD subtype? *Thorax* 2020;75:901-903.
172. Lo Bello F, Hansbro PM, Donovan C, Coppolino I, Mumby S, Adcock IM, **Caramori G** (Pharmacology and Pharmacy 176/353, Impact Factor 2.7, 2024, Q2). New drugs under development for COPD. *Expert Opin Emerg Drugs* 2020;25:419-431.
173. Sabbatino F, Liguori L, Polcaro G, Salvato I, **Caramori G**, Salzano FA, Casolaro V, Stellato C, Col JD, Pepe S (Biochemistry and Molecular Biology 74/320, Impact Factor 4.9, 2024, Q1). Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients. *Int J Mol Sci* 2020;21:7295. doi: 10.3390/ijms21197295.
174. Ricciardi L, Giurato G, Memoli D, Pietrafesa M, Dal Col J, Salvato I, Nigro A, Vatrella A, **Caramori G**, Casolaro V, Stellato C (Immunology 32/184, Impact Factor 5.9, 2024, Q1). Posttranscriptional gene regulatory networks in chronic airway inflammatory diseases: *In silico* mapping of RNA-binding protein expression in airway epithelium. *Front Immunol* 2020 Oct 16;11:579889. doi: 10.3389/fimmu.2020.579889. eCollection 2020.
175. Alderawi A, **Caramori G**, Baker EH, Hitchings AW, Rahman I, Rossios C, Adcock I, Cassolari P, Papi A, Ortega VE, Curtis JL, Dunmore S, Kirkham P (Respiratory System 30/108, Impact Factor 3.4, 2024, Q2). FN3K expression in COPD: a potential comorbidity factor for cardiovascular disease. *BMJ Open Respir Res* 2020;7:e000714. doi: 10.1136/bmjresp-2020-000714.
176. Perrotta F, Nigro E, Pafundi PC, Polito R, Nucera F, Scialò F, **Caramori G**, Bianco A, Daniele A (Respiratory System 61/108, Impact Factor 2.1, 2024, Q3). Adiponectin is associated with neutrophils to lymphocyte ratio in patients with chronic obstructive pulmonary disease. *COPD* 2021;18:70-75.
177. Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, **Caramori G**, Cari L, Fan Chung K, Diamant Z, Eguiluz-Gracia I, Knol EF, Kolios A, Levi-Schaffer F, Nocentini G, Palomares O, Redegeld F, Van Esch B, Stellato C (Allergy 1/39, Impact Factor 12, 2024, Q1). Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases-An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). *Allergy* 2021;76:90-113.
178. Williams TC, Jackson DJ, Maltby S, Walton RP, Ching YM, Glanville N, Singanayagam A, Brewins JJ, Clarke D, Hirsman AG, Loo SL, Wei L, Beale JE, Casolari P, **Caramori G**, Papi A, Belvisi M, Wark PAB, Johnston SL, Edwards MR, Bartlett NW (Respiratory System 15/108, Impact Factor 5.3, 2024, Q1). Rhinovirus-induced CCL17 and CCL22 in asthma exacerbations and differential regulation by STAT6. *Am J Respir Cell Mol Biol* 2021;64:344-356.

179. D'Anna SE, Maniscalco M, Cappello F, Carone M, Motta A, Balbi B, Ricciardolo FLM, **Caramori G**, Stefano AD (Medicine, General and Internal 41/333, Impact Factor 4.3, 2021, Q1). Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. *Ann Med* 2021;53:135-150.
180. Bonaccorsi I, Carrega P, Venanzi Rullo E, Ducatelli R, Falco M, Freni J, Miceli M, Cavaliere R, Fontana V, Versace A, **Caramori G**, David A, Nunnari G, Ferlazzo G (Immunology 109/184, Impact Factor 2.8, 2024, Q3). HLA-C\*17 in COVID-19 patients: hints for associations with severe clinical outcome and cardiovascular risk. *Immunol Lett* 2021;234:44-46.
181. Nucera F, Lo Bello F, Shen SS, Ruggeri P, Coppolino I, Di Stefano A, Stellato C, Casolaro V, Hansbro PM, Adcock IM, **Caramori G** (Pharmacology and Pharmacy 112/353, Impact Factor 3.5, 2024, Q2). Role of atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD. *Curr Med Chem* 2021;28:2577-2653.
182. Adeyoye D, Elneima O, Daines L, Poinasamy K, Quint JK, Walker S, Brightling CE, Siddiqui S, Hurst JR, Chalmers JD, Pfeffer PE, Novotny P, Drake TM, Heaney LG, Rudan I, Sheikh A, De Soyza A; **International COVID-19 Airways Diseases Group (Gaetano Caramori represented Italy) (Respiratory System 1/65, Impact Factor 102.642, 2021, Q1)** (Respiratory System 1/108, Impact Factor 32.8, 2024, Q1). The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. *Lancet Respir Med* 2021;9:1467-1478.
183. Arpinelli F, Nucera F, Ruggeri P, Lo Bello F, Magnoni MS, **Caramori G**. [Risk of diabetes mellitus during regular long-term inhaled glucocorticoid treatment in COPD patients: narrative review of the literature]. *Recenti Prog Med* 2021;112:668-677.
184. Adeyoye D, Agarwal D, Barnes PJ, Bonay M, van Boven JF, Bryant J, **Caramori G**, Dockrell D, D'Urzo A, Ekström M, Erhabor G, Esteban C, Greene CM, Hurst J, Juvekar S, Khoo EM, Ko FW, Lipworth B, López-Campos JL, Maddocks M, Mannino DM, Martinez FJ, Martinez-Garcia MA, McNamara RJ, Miravittles M, Pinnock H, Pooler A, Quint JK, Schwarz P, Slavich GM, Song P, Tai A, Watz H, Wedzicha JA, Williams MC, Campbell H, Sheikh A, Rudan I (Public, Environmental and Occupational Health 48/421, Impact Factor 4.3, 2024, Q1). Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. *J Glob Health* 2021 Oct 9;11:15003. doi: 10.7189/jogh.11.15003. eCollection 2021.
185. Kim RY, Sunkara KP, Bracke KR, Jarnicki AG, Donovan C, Hsu AC, Ieni A, Beckett EL, Galvão I, Wijnant S, Ricciardolo FL, Di Stefano A, Haw TJ, Liu G, Ferguson AL, Palendira U, Wark PA, Conickx G, Mestdagh P, Brusselle GG, **Caramori G**, Foster PS, Horvat JC, Hansbro PM (Medicine, Research and Experimental 3/195, Impact Factor 14.6, 2024, Q1). A microRNA-21-mediated SATB1/S100A9/NF-κB axis promotes chronic obstructive pulmonary disease pathogenesis. *Sci Transl Med* 2021 Nov 24;13(621):eaav7223. doi: 10.1126/scitranslmed.aav7223. Epub 2021 Nov 24.
186. Uwagboe I, Adcock IM, Lo Bello F, **Caramori G**, Mumby S. New drugs under development for COPD. *Minerva Med* 2022;113:471-496.
187. Nucera F, Mumby S, Paudel KR, Dharwal V, Di Stefano A, Casolaro V, Hansbro PM, Adcock IM, **Caramori G**. Role of oxidative stress in the pathogenesis of COPD. *Minerva Med* 2022;113:370-404.
188. Nucera F, Bianco A, David T, Salvato I, Adcock IM, **Caramori G**. Treatable traits in COPD patients. *Minerva Med* 2022;113:449-459.
189. **Caramori G**. COPD: from bench to bedside. *Minerva Med* 2022;113:367-369.
190. **Caramori G**, Nucera F, Mumby S, Lo Bello F, Adcock IM (Medicine, Research and Experimental 17/195, Impact Factor 10.3, 2024, Q1). Corticosteroid resistance in asthma: Cellular and molecular mechanisms. *Mol Aspects Med* 2022 Jun;85:100969. doi: 10.1016/j.mam.2021.100969. Epub 2021 Jun 3.

191. Di Stefano A, Dossena F, Gnemmi I, D'Anna SE, Brun P, Balbi B, Piraino A, Spanevello A, Nucera F, Carriero V, Bertolini F, Maniscalco M, Adcock IM, **Caramori G**, Ricciardolo FLM (Pharmacology and Pharmacy 162/353, Impact Factor 2.8, 2024, Q2). Decreased humoral immune response in the bronchi of rapid decliners with chronic obstructive pulmonary disease. *Respir Res* 2022;23:200.
192. Campana S, De Pasquale C, Sidoti Migliore G, Pezzino G, Cavaliere R, Venanzi Rullo E, Nunnari G, **Caramori G**, David A, Bonaccorsi I, Pollicino T, Carrega P, Ferlazzo G (Immunology 86/184, Impact Factor 3.4, 2024, Q2). Cutting edge: hyperinflammatory monocytes expressing CD56 abound in severe COVID-19 patients. *J Immunol* 2022;209:655-659.
193. Liu G, Jarnicki AG, Paudel KR, Lu W, Wadhwa R, Philp AM, Van Eeckhoutte H, Marshall JE, Malya V, Katsifis A, Fricker M, Hansbro NG, Dua K, Kermani NZ, Eapen MS, Tiotiu A, Chung KF, **Caramori G**, Bracke K, Adcock IM, Sohal SS, Wark PA, Oliver BG, Hansbro PM (Respiratory System 2/108, Impact Factor 21, 2024, Q1). Adverse roles of mast cell chymase-1 in chronic obstructive pulmonary disease. *Eur Respir J* 2022;60:2101431. doi: 10.1183/13993003.01431-2021. Print 2022 Dec.
194. Salvato I, Ricciardi L, Nucera F, Nigro A, Dal Col J, Monaco F, **Caramori G**, Stellato C (Respiratory System 61/108, Impact Factor 2.1, 2024, Q3). RNA-binding proteins as a molecular link between COPD and lung cancer. *COPD* 2023; 20:18-30.
195. Bugiardini R, Nava S, **Caramori G**, Yoon J, Badimon L, Bergami M, Cenko E, David A, Demiri I, Dorobantu M, Fronea O, Jankovic R, Kedev S, Ladjevic N, Lasica R, Loncar G, Mancuso G, Mendieta G, Miličić D, Mjehović P, Pašalić M, Petrović M, Poposka L, Scarpone M, Stefanovic M, van der Schaar M, Vasiljevic Z, Vavlukis M, Vega Pittao ML, Vukomanovic V, Zdravkovic M, Manfrini O (Cardiac and Cardiovascular Systems 8/230, Impact Factor 13.3, 2024, Q1). Sex differences and disparities in cardiovascular outcomes of COVID-19. *Cardiovasc Res* 2023;119:1190-1201. doi: 10.1093/cvr/cvad011
196. Scaramuzza G\*, Nucera F\*, Asmundo A, Messina R, Mari M, Montanaro F, Johansen MD, Monaco F, Fadda G, Tuccari G, Hansbro NG, Hansbro PM, Hansel TT, Adcock IM, David A, Kirkham P, **Caramori G**, Volta CA, Spadaro S (Immunology 63/184, Impact Factor 4.1, 2024, Q2). Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. *J Inflamm* 2023; Mar 20;20(1):11. doi: 10.1186/s12950-023-00333-2. \*Both Authours contributed equally to this work.
197. Salvato I, Ricciardi L, Dal Col J, Nigro A, Giurato G, Memoli D, Sellitto A, Lamparelli EP, Crescenzi MA, Vitale M, Vatrella A, Nucera F, Brun P, Caicci F, Dama P, Stiff T, Castellano L, Idrees S, Johansen MD, Faiz A, Wark PA, Hansbro PM, Adcock IM, **Caramori G**, Stellato C (Immunology 32/184, Impact Factor 5.9, 2024, Q1). Expression of targets of the RNA-binding protein AUF-1 in human airway epithelium indicates its role in cellular senescence and inflammation. *Front Immunol.* 2023 Jul 7;14:1192028. doi: 10.3389/fimmu.2023.1192028. eCollection 2023.
198. Bergami M, Manfrini O, Nava S, **Caramori G**, Yoon J, Badimon L, Cenko E, David A, Demiri I, Dorobantu M, Fabin N, Gheorghe-Fronea O, Jankovic R, Kedev S, Ladjevic N, Lasica R, Loncar G, Mancuso G, Mendieta G, Miličić D, Mjehović P, Pašalić M, Petrović M, Poposka L, Scarpone M, Stefanovic M, van der Schaar M, Vasiljevic Z, Vavlukis M, Vega Pittao ML, Vukomanovic V, Zdravkovic M, Bugiardini R (Cardiac and Cardiovascular Systems 41/230, Impact Factor 5.3, 2024, Q1). Relationship between azithromycin and cardiovascular outcomes in unvaccinated patients With COVID-19 and preexisting cardiovascular disease. *J Am Heart Assoc* 2023;12:e028939. doi: 10.1161/JAHA.122.028939. Epub 2023 Jul 14.
199. Mumby S, Perros F, Grynblat J, Manaud G, Papi A, Casolari P, **Caramori G**, Humbert M, John Wort S, Adcock IM (Pharmacology and Pharmacy 162/353, Impact Factor 2.8, 2024, Q2). Differential responses of pulmonary vascular cells from PAH

- patients and controls to TNF $\alpha$  and the effect of the BET inhibitor JQ1. *Respir Res* 2023;24(1):193. doi: 10.1186/s12931-023-02499-y.
200. Sahu P, Donovan C, Paudel KR, Pickles S, Chimankar V, Kim RY, Horvart JC, Dua K, Ieni A, Nucera F, Bielefeldt-Ohmann H, Mazilli S, **Caramori G**, Lyons JG, Hansbro PM (Oncology 127/327, Impact Factor 3.3, 2024, Q2). Pre-clinical lung squamous cell carcinoma mouse models to identify novel biomarkers and therapeutic interventions. *Front Oncol* 2023 Sep 25;13:1260411. doi: 10.3389/fonc.2023.1260411. eCollection 2023.
201. Liu G, Haw TJ, Starkey MR, Philp AM, Pavlidis S, Nalkurthi C, Nair PM, Gomez HM, Hanish I, Hsu AC, Hortle E, Pickles S, Rojas-Quintero J, Estepar RSJ, Marshall JE, Kim RY, Collison AM, Mattes J, Idrees S, Faiz A, Hansbro NG, Fukui R, Murakami Y, Cheng HS, Tan NS, Chotirmall SH, Horvat JC, Foster PS, Oliver BG, Polverino F, Ieni A, Monaco F, **Caramori G**, Sohal SS, Bracke KR, Wark PA, Adcock IM, Miyake K, Sin DD, Hansbro PM (Multidisciplinary Sciences 10/136, Impact Factor 15.7, 2024, Q1). TLR7 promotes smoke-induced experimental lung damage through the activity of mast cell tryptase. *Nat Commun* 2023;14:7349. doi: 10.1038/s41467-023-42913-z.
202. Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, **Caramori G**, Cari L, Chung KF, Diamant Z, Eguiluz-Gracia I, Knol EF, Jesenak M, Levi-Schaffer F, Nocentini G, O'Mahony L, Palomares O, Redegeld F, Sokolowska M, Van Esch BCAM, Stellato C (Allergy 1/39, Impact Factor 12, 2024, Q1). Metabolic pathways in immune senescence and inflammaging: Novel therapeutic strategy for chronic inflammatory lung diseases. An EAACI position paper from the Task Force for Immunopharmacology. *Allergy* 2024;79: 1089-1122.
203. Casciaro M, Gangemi S, **Caramori G**, Nucera F, Tuccari G, Ieni A (Pathology 24/90, Impact Factor 3.2, 2024, Q2). IL-33 immunohistochemical pattern of expression in neoplastic and nonneoplastic peripheral lung tissues of stage 1 o 2 lung adenocarcinoma. *Pathol Res Pract* 2024 Feb 13;255:155208. doi: 10.1016/j.prp.2024.155208. Online ahead of print.
204. Nucera F, Bonina L, Cipolla A, Pirina P, Hansbro PM, Adcock IM, **Caramori G**. Poxviridae Pneumonia. *Adv Exp Med Biol* 2024;1451:183-204. doi: 10.1007/978-3-031-57165-7\_12.
205. Nucera F, Di Stefano A, Ricciardolo FLM, Gnemmi I, Pizzimenti C, Monaco F, Tuccari G, **Caramori G**, Ieni A (Biochemistry and Molecular Biology 74/320, Impact Factor 4.9, 2024, Q1). Role of ATG4 Autophagy-Related Protein Family in the Lower Airways of Patients with Stable COPD. *Int J Mol Sci* 2024;25:8182. doi: 10.3390/ijms2515818
206. Farrell LA, O'Rourke MB, Padula MP, Souza-Fonseca-Guimaraes F, **Caramori G**, Wark PAB, Dharmage SC, Hansbro PM (Biochemistry and Molecular Biology 135/320, Impact Factor 3.6, 2024, Q2). The Current molecular and cellular landscape of chronic obstructive pulmonary disease (COPD): a review of therapies and efforts towards personalized treatment. *Proteomes* 2024;12:23. doi: 10.3390/proteomes12030023.
207. Marchese A, Accogli R, Frizzelli A, De Simoni A, Bondarenko O, Pisi R, **Caramori G**, Pelà G, Majori M, Gnetti L, Aluia A, D'Aloisio L, Chetta A, Aiello M (Medicine, Research and Experimental 115/195, Impact Factor 2,2 2024, Q3). Onset of ANCA-positive EGPA with bilateral pleural effusion: a case report. *Curr Med Res Opin* 2024;40:2209-2213. doi: 10.1080/03007995.2024.2427882. Epub 2024 Nov 19.
208. Heinemann L, Adcock I, Chung KF, Lollinga W, Hylkema MN, Papi A, **Caramori G**, Kirkham PA (Immunology 63/184, Impact Factor 4.1, 2024, Q2). Auto-antibodies against carbonyl-modified vimentin in COPD: potential role as a biomarker. *J Inflamm (Lond)* 2025;22:7. doi: 10.1186/s12950-025-00434-0.
209. Accogli R, Frizzelli A, Bondarenko O, Tzani P, Calzetta L, Marchese A, Pisi R, **Caramori G**, Chetta A, Aiello (Respiratory System 76/108, Impact Factor 1.6, 2024, Q3). Breathing pattern and ventilatory response to exercise in patients with chronic

obstructive pulmonary disease. *Respir Physiol Neurobiol* 2025;335:104413. doi: 10.1016/j.resp.2025.104413.

210. Liu G, Hsu AC, Geirnaert S, Cong C, Nair PM, Shen S, Marshall JE, Haw TJ, Fricker M, Philp AM, Hansbro NG, Pavlidis S, Guo Y, Burgess JK, Castellano L, Ieni A, **Caramori G**, Oliver BGG, Chung KF, Adcock IM, Knight DA, Polverino F, Bracke K, Wark PA, Hansbro PM (*Medicine, Research and Experimental* 10/195, Impact Factor 12, 2024, Q1). Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease. *Mol Ther* 2025;33:917-932. doi: 10.1016/j.ymthe.2025.01.032. Epub 2025 Jan 21.

211. Marchese A, Frizzelli A, Accogli R, Aluia A, Tessitore C, Bondarenko O, **Caramori G**, Chetta A, Aiello M (*Medicine, Research and Experimental* 115/195, Impact Factor 2,2 2024, Q3). A rare case of sudden blindness following mepolizumab withdrawal in EGPA. *Curr Med Res Opin* 2025 May;41(5):761-766. doi: 10.1080/03007995.2025.2517693

212. **Caramori G**, Rossi F, Adcock IM (*Medicine, Research and Experimental* 10/195, Impact Factor 12, 2024, Q1). GDF11: A promising new drug target for pulmonary fibrosis? *Mol Ther* 2025;33:4676-4679. doi: 10.1016/j.ymthe.2025.09.016

213. Idrees S, Chen H, Sadaf T, Rehman SF, Johansen MD, Paudel KR, Liu G, Wang Y, Luecken MD, Hortle E, Philp AS, Budden KF, O'Rourke M, Kaiko GE, Lucas SEM, Dickinson JL, Allen PC, Powell JE, Zhang LY, Chambers DC, Corte T, **Caramori G**, Sauler M, Wark PA, Gote-Schniering J, Lehmann M, Conlon TM, Kapellos TS, Yildirim AÖ, Faner R, Dharmage SC, Wheelock CE, van den Berge M, Nawijn MC, Polverino F, Belz GT, Chotirmall SH, Segal LN, Faiz A, Hansbro PM (*Respiratory System* 5/108, Impact Factor 10.4, 2024, Q1). Multi-omics to study chronic respiratory diseases and viral infections. *Eur Respir Rev* 2026;35:240286. doi: 10.1183/16000617.0286-2024. Print 2026 Jan.

214.

Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, **Caramori G**, Cari L, Chung KF, Diamant Z, Eguluz-Gracia I, Knol EF, Jesenak M, Levi-Schaffer F, Nocentini G, O'Mahony L, Palomares O, Redegeld F, Sokolowska M, Van Esch B, Zurlo M, Stellato C (*Allergy* 1/39, Impact Factor 12, 2024, Q1). Update on Non-Biological and RNA-Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper. *Allergy*. 2026 Feb 7. doi: 10.1111/all.70235. Online ahead of print.

## **b. Publications in Italian Journals not listed in the Current Contents and/or Medline**

1. Fabbri L, **Caramori G**, Guidoboni A, Ciaccia A. Gli antagonisti dei leucotrieni: nuove speranze nella terapia dell'asma?. *Rassegna di Patologia dell'Apparato Respiratorio* 1994;9:223-237.

2. Fabbri L, Ferrari M, Cosma P, **Caramori G**, Ciaccia A. Marcatori infiammatori nella diagnosi e nel monitoraggio dell' asma. *Rassegna di Patologia dell'Apparato Respiratorio* 1995;10:43-58.

3. Fabbri L, Ferrari M, **Caramori G**, Ciaccia A. Nuove linee guida internazionali per la terapia farmacologica dell'asma. *Rassegna di Patologia dell'Apparato Respiratorio* 1995;10(suppl 1):119-120.

4. Fabbri L, Ferrari M, **Caramori G**, Ciaccia A. Ruolo dei beta2 agonisti a lunga durata di azione nella gestione del paziente asmatico. *Rassegna di Patologia dell'Apparato Respiratorio* 1995;10(suppl 1):138-139.

5. Fabbri L, Ferrari M, **Caramori G**, Ciaccia A. Stato dell'arte degli antileucotrieni nella terapia dell'asma. *Rassegna di Patologia dell'Apparato Respiratorio* 1995;10(suppl 1):175.

6. Fabbri L, Ferrari M, **Caramori G**, Ciaccia A. Broncodilatatori nella terapia delle broncopneumopatie croniche ostruttive. Rassegna di Patologia dell'Apparato Respiratorio 1996;11:148-163.
7. Fabbri L, **Caramori G**, Ciaccia A. Sintesi delle nuove linee guida internazionali per la terapia farmacologica dell'asma. Aggiornamento Medico 1996;20:1-8.
8. Fabbri L, **Caramori G**, Ciaccia A.  $\beta$ 2 agonisti inalatori nel trattamento dell'asma bronchiale e delle broncopneumopatie croniche ostruttive. Aggiornamento Medico 1996;20:149-155.
9. Fabbri LM, Ricci G, Fugagnoli A, **Caramori G**, Alvisi V, Ciaccia A. Sindrome epatopolmonare. Rassegna di Patologia dell'Apparato Respiratorio 1996;11:478-484.
10. Fabbri LM, **Caramori G**, Ciaccia A. Glucocorticoidi per via inalatoria nel trattamento della patologia polmonare dell'adulto. Aggiornamento Medico 1996;20:260-269.
11. Fabbri LM, Cremona G, **Caramori G**, Piattella M, Romagnoli M, Beghè B, Panella GL, Ciaccia A. La scoperta dell'ossido nitrico endogeno ha aperto nuove prospettive terapeutiche nella patologia polmonare dell'adulto?. Rassegna di Patologia dell'Apparato Respiratorio 1996;11:554-576.
12. Fabbri LM, Casoni GL, **Caramori G**, Ciaccia A. Ipertensione polmonare cronica nell'adulto. Aggiornamento Medico 1997;21:34-44.
13. Fabbri LM, **Caramori G**, Beghè B, Ciaccia A. Asma. Rassegna di Patologia dell'Apparato Respiratorio 1997;12:497-499. Available online at [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
14. Fabbri LM, **Caramori G**, Beghè B, Ciaccia A. Nuove iniziative internazionali sulle linee guida per la broncopneumopatia cronica ostruttiva. Rassegna di Patologia dell'Apparato Respiratorio 1997;12:510-511. Available online at [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
15. Fabbri LM, **Caramori G**, Beghè B, Mapp C, Saetta M, Maestrelli P, Ciaccia A. Definizione e basi biologiche della broncopneumopatia cronica ostruttiva. Rassegna di Patologia dell'Apparato Respiratorio 1997;12:515-518. Available online at [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
16. **Caramori G**, Fabbri LM, Beghè B, Ciaccia A. La terapia farmacologica dell'asma nei prossimi cinque anni: l'opinione dello specialista. Giorn Ital Allergol Immunol Clin 1997;7:137-150.
17. Fabbri LM, **Caramori G**, Beghè B, Ciaccia A. Le linee guida vengono seguite?. Rassegna di Patologia dell'Apparato Respiratorio 1997;12:696-702. Disponibile online nel sito [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
18. Braccioni F, Pasquini C, Ravenna F, Calia N, Milani G, Pivrotto F, **Caramori G**, Fabbri LM, Ciaccia A. Donna non fumatrice con asma bronchiale difficile da controllare. Rassegna di Patologia dell'Apparato Respiratorio 1998;13:73-75. Available online at [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
19. Ricciardolo FL, **Caramori G**. Ruolo delle chinine nella patologia polmonare dell'adulto. Rassegna di Patologia dell'Apparato Respiratorio 1998;13:572-596. Disponibile online nel sito [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)
20. Ciaccia A, Papi A, **Caramori G**, Beghè B, Fabbri LM. Patogenesi della broncopneumopatia cronica ostruttiva. L'Arcispedale S. Anna di Ferrara 1998;47:25-37.
21. Ciaccia A, Braccioni F, **Caramori G**. Tubercolosi: vaccinazione e chemioprolifassi come prevenzione. Professione Sanità Pubblica e Medicina Pratica 1998;6:13-17.
22. Ravenna F, Braccioni F, Castelletti ML, **Caramori G**, Ciaccia A. Studio clinico-epidemiologico sulle neoplasie polmonari maligne. Confronto tra 2 coorti di pazienti nei quinquenni 1981-5 e 1991-5. Rassegna di Patologia dell'Apparato Respiratorio 1999;14:8-14. Disponibile online nel sito [http://www.pacinimedica.it/index\\_dinamico.htm](http://www.pacinimedica.it/index_dinamico.htm)

23. **Caramori G**, Casoni GL, Papi A, Ciaccia A, Fabbri LM. Nuove strategie terapeutiche delle broncopneumopatie croniche ostruttive. *Aggiornamento Medico* 2001;25:53-62. Disponibile online nel sito <http://www.kurtis.it>
24. Calia N, Ravenna F, Castelletti ML, Pasquini C, Magalotti G, Casoni G, Richeldi L, **Caramori G**, Papi A, Ciaccia A. Tubercolosi extrapolmonare a carico dell'apparato genitale femminile con reazione a catena polimerasica negativa per micobatterio tubercolare. *Rassegna di Patologia dell'Apparato Respiratorio* 2001;16: 448-451. Disponibile online nel sito [http://www.pacinimedicina.it/index\\_dinamico.htm](http://www.pacinimedicina.it/index_dinamico.htm)
25. **Caramori G**, Casoni G, Papi A, Ciaccia A. I glucocorticoidi inalatori sono poco efficaci nel trattamento delle BPCO in fase stabile. *Società Italiana di Medicina Generale* 2001;19-22. Disponibile online nel sito <http://www.simg.it>
26. **Caramori G**, Richeldi L, Roggeri A, Zucchi A, Papi A, Fabbri LM, Ciaccia A. Polmoniti da parassiti (parte 1). *Aggiornamento Medico* 2002;26:18-24. Disponibile online nel sito <http://www.kurtis.it>
27. **Caramori G**, Richeldi L, Roggeri A, Zucchi A, Papi A, Fabbri LM, Ciaccia A. Polmoniti da parassiti (parte 2). *Aggiornamento Medico* 2002;26:53-59. Disponibile online nel sito <http://www.kurtis.it>
28. **Caramori G**, Guzzinati I, Pasquini C, Casoni G, Ravenna F, Calia N, Castelletti ML, Boniotti A, Braccioni F, Arar O, Papi A, Ciaccia A. Anatomia e fisiologia clinica della pleura. *Aggiornamento Medico* 2002;26:262-265. Disponibile online nel sito <http://www.kurtis.it>
29. **Caramori G**, Guzzinati I, Pasquini C, Casoni G, Ravenna F, Calia N, Castelletti ML, Boniotti A, Braccioni F, Arar O, Papi A, Ciaccia A. Classificazione e metodi di indagine del pneumotorace. *Aggiornamento Medico* 2002;26:266-271. Disponibile online nel sito <http://www.kurtis.it>
30. **Caramori G**, Guzzinati I, Pasquini C, Casoni G, Ravenna F, Calia N, Castelletti ML, Boniotti A, Braccioni F, Arar O, Papi A, Ciaccia A. Trattamento del pneumotorace. *Aggiornamento Medico* 2002;26:272-275. Disponibile online nel sito <http://www.kurtis.it>
31. Bettoncelli G, D'Ambrosio G, Invernizzi G, **Caramori G**, Spanevello A, Brazzola G, Neri M. Implementazione delle linee guida sull'asma bronchiale in Italia: l'opinione del medico di medicina generale. *Rassegna di Patologia dell'Apparato Respiratorio* 2002;17:450-458. Disponibile online nel sito [http://www.pacinimedicina.it/index\\_dinamico.htm](http://www.pacinimedicina.it/index_dinamico.htm)
32. **Caramori G**, Papi A. Virus ed attacchi d'asma. *Società Italiana di Medicina Generale* 2002;22. Disponibile online nel sito <http://www.simg.it>
33. **Caramori G**, Papi A, Ciaccia A. Sindrome respiratoria acuta severa (SARS). *Aggiornamento Medico* 2003;27:219-223. Disponibile online nel sito <http://www.kurtis.it>
34. Bettoncelli G, **Caramori G**, Tosatto R, Arpinelli F, Visonà G, Invernizzi G, Gerace A. Risultati della prima fase dello studio CORDIS in medicina generale. *Società Italiana di Medicina Generale* 2003;43-47. Disponibile online nel sito <http://www.simg.it>
35. **Caramori G**, Papi A, Ciaccia A. Broncodilatatori nell'asma e nelle broncopneumopatie croniche ostruttive. *Aggiornamento Medico* 2003;27:263-273. Disponibile online nel sito <http://www.kurtis.it>
36. Guzzinati I, Ravenna F, Pasquini C, Castelletti ML, Calia N, Boniotti A, Cavallesco G, Lusuardi M, **Caramori G**, Beccati D, Papi A, Ciaccia A. Basi fisiopatologiche per la diagnosi delle malattie della pleura nell'adulto. Parte 1. *Rass Patol App Respir* 2003;18:311-320. Disponibile online nel sito [http://www.pacinimedicina.it/index\\_dinamico.htm](http://www.pacinimedicina.it/index_dinamico.htm)
37. Guzzinati I, Ravenna F, Pasquini C, Castelletti ML, Calia N, Boniotti A, Cavallesco G, Lusuardi M, **Caramori G**, Beccati D, Papi A, Ciaccia A. Basi fisiopatologiche per la diagnosi delle malattie della pleura nell'adulto. Parte 2. *Rass Patol App Respir*

- 2003;18:403-411. Disponibile online nel sito [http://www.pacinimedicina.it/index\\_dinamico.htm](http://www.pacinimedicina.it/index_dinamico.htm)
38. **Caramori G**, Papi A, Ciaccia A. Teofillina: effetti polmonari ed extrapolmonari nei pazienti con asma e BPCO; nuove prospettive. Rivista SIMG 2003;(3):15-19. Disponibile online nel sito <http://www.simg.it>
39. **Caramori G**, Papi A, Ciaccia A. La teofillina nell'asma e nella BPCO: nuove prospettive (2° parte). Società Italiana di Medicina Generale 2003;(4-5):16-18. Disponibile online nel sito <http://www.simg.it>
40. **Caramori G**, Papi A, Ciaccia A. La teofillina nella BPCO: nuove prospettive (3° parte). Società Italiana di Medicina Generale 2004;1-4. Available online at <http://www.simg.it>
41. **Caramori G**. Versamento ed empiema pleurico parapneumonico nell'adulto. Aggiornamento Medico 2004;28:45. Disponibile online nel sito <http://www.kurtis.it>
42. **Caramori G**, Guzzinati I, Pasquini C, Ravenna F, Calia N, Arar A, Casolari P, Castelletti ML, Boniotti A, Gennari A, Cavallesco G, Papi A, Ciaccia A. Versamento ed empiema pleurico parapneumonico nell'adulto: dall'eziologia alle manifestazioni cliniche. Aggiornamento Medico 2004;28:46-50. Disponibile online nel sito <http://www.kurtis.it>
43. **Caramori G**, Guzzinati I, Pasquini C, Ravenna F, Calia N, Arar A, Casolari P, Castelletti ML, Boniotti A, Gennari A, Cavallesco G, Papi A, Ciaccia A. Versamento ed empiema pleurico parapneumonico nell'adulto: diagnosi e trattamento. Aggiornamento Medico 2004;28:51-58. D Disponibile online nel sito <http://www.kurtis.it>
44. **Caramori G**, Manta C, Arar O, Casolari P, Marku B, Papi A, Ciaccia A. Ruolo dei fattori di crescita dell'endotelio vascolare e dei loro recettori nella patogenesi delle malattie polmonari dell'adulto: fisiologia. Rass Patol App Respir 2004;19:100-109.
45. **Caramori G**, Manta C, Arar O, Casolari P, Marku B, Papi A, Ciaccia A. Ruolo dei fattori di crescita dell'endotelio vascolare e dei loro recettori nella patogenesi delle malattie polmonari dell'adulto: patologia. Rass Patol App Respir 2004;19:262-274.
46. **Caramori G**, Arar O, Casolari P, Marku B, Guzzinati I, Ciaccia A, Papi A. Fattori di trascrizione: la nuova frontiera della ricerca nell'asma bronchiale e nelle broncopneumopatie croniche ostruttive. Rass Patol App Respir 2004;19:310-322.
47. **Caramori G**, Pasquinelli P, Bellagamba MP. Sport e inquinamento atmosferico. Pneumologia Pediatrica 2004;16:27-34.
48. **Caramori G**, Arar O, Casolari P, Marku B, Gnani MC, Guzzinati I, Papi A, Ciaccia A. Fattori di trascrizione: la nuova frontiera della ricerca nell'asma bronchiale e nelle broncopneumopatie croniche ostruttive. Basi fisiologiche. I parte. Annali degli Ospedali San Camillo e Forlanini 2004;6:26-38.
49. **Caramori G**, Arar O, Casolari P, Marku B, Gnani MC, Guzzinati I, Papi A, Ciaccia A. Fattori di trascrizione: la nuova frontiera della ricerca nell'asma bronchiale e nelle broncopneumopatie croniche ostruttive. Basi fisiologiche. II parte. Annali degli Ospedali San Camillo e Forlanini 2004;6:23-39.
50. **Caramori G**, Bettoncelli G, Papi A. Controllo dell'asma e delle BPCO nella medicina Generale. Società Italiana di Medicina Generale Online 2005:1-9. Disponibile online nel sito <http://www.simg.it>
51. **Caramori G**, Zanforlin A, Casolari P, Zanforlin M, Contoli M, Ciaccia A, Papi A. Morte per asma. Parte I: fenotipi clinici, epidemiologia e fattori di rischio. Rass Patol App Respir 2005;20:25-36.
52. **Caramori G**, Zanforlin A, Casolari P, Zanforlin M, Contoli M, Ciaccia A, Papi A. Morte per asma. Parte II: patogenesi, quadro anatomo-patologico, diagnosi differenziale e prevenzione. Rass Patol App Respir 2005;20:129-143.
53. Contoli M, **Caramori G**, Casolari P, Ciaccia A, Papi A. Ruolo delle infezioni virali nelle riacutizzazioni asmatiche. Rass Patol App Respir 2005;20:246-253.

54. Ravenna F, Arar O, Calia N, Pasquini C, Dilani G, Bianchini E, Guzzinati I, Boniotti A, Ciaccia Am Cavallesco G, **Caramori G**, Papi A. Carcinoma adenoido-cistico tracheale simulante una grave riacutizzazione asmatica. *Rass Patol App Respir* 2006;21:108-112.
55. **Caramori G**, Nunzio Calia N, Mazzoni F, Farina E, Gnesini G, Contoli M, Vicentini L, Rossi R, Casolari P, Guzzinati I, Boniotti A, Pasquini C, Ravenna F, Ciaccia A, Cavallesco G, Papi A. Polmonite da ipersensibilità da antigeni aviari in un italiano adulto. *Aggiornamento Medico* 2007;31:302-311. Disponibile online nel sito <http://www.kurtis.it>
56. **Caramori G**, Mazzoni F, Casolari P, Contoli M, Scavello S, Lasagna L, Ciaccia A, Papi A. Cellule staminali e patologia polmonare dell'adulto. *Aggiornamento Medico* 2008;32:13-21. Disponibile online nel sito <http://www.kurtis.it>
57. **Caramori G**, Contoli M, Papi A. Changing pharmacological approaches in mild asthma. *Italian Journal of Allergy and Clinical Immunology* 2009;19:144-148.
58. **Caramori G**, Paredi P. Controllo della broncopneumopatia cronica ostruttiva in Italia. *Aggiornamento Medico* 2009;33:8-11. Disponibile online nel sito <http://www.kurtis.it>
59. Saturni S, **Caramori G**, Paredi P, Casolari P, Contoli M, Ciaccia A, Papi A. Ruolo dello stress ossidativo nella patogenesi delle broncopneumopatie croniche ostruttive in fase stabile. *Minerva Pneumologica* 2009; 48:111-128.
60. Carone M, Arpinelli F, Pieretto A, Tosatto R, **Caramori G**, Bertolotti G, Bettoncelli G. Quality of life in Asthma and COPD: is it measurable in primary care?. *Rass Patol App Respir* 2009;24:220-226.
61. Saturni S, **Caramori G**, Paredi P, Casolari P, Contoli M, Ciaccia A, Papi A. Ruolo dei marcatori non invasivi di stress ossidativo nelle broncopneumopatie croniche ostruttive. *Rass Patol App Respir* 2009;24:287-300.
62. Marku B, Pauletti A, Forini G, Gnesini G, **Caramori G**, Papi A, Contoli M. Ruolo delle infezioni respiratorie nelle riacutizzazioni di BPCO. *Rass Patol App Respir* 2012;27:131-139.
63. **Caramori G**, Casolari P, Carone M, Bertorelli G, Banfi P, Andò F. Trattamento personalizzato dei pazienti con BPCO in fase stabile. *Rass Patol App Respir* 2016;31:83-90.
64. Irene Coppolino, Paolo Ruggeri, Mario Francesco Cannavò, Francesco Nucera, Federica Lo Bello, Rocco Donato, Ignazio Salamone, Enrico Potenza, Giovanni Bartoloni, **Gaetano Caramori**, Giuseppe Girbino. An unusual cause of chest pain. *APMB - Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche* (2018), 106(1):A3(1-6)
65. Domenica Catalano, Antonella Sacco, Ignazio Salamone, Alfio Proietto, Irene Coppolino, **Gaetano Caramori**, Paolo Ruggeri, Giuseppe Girbino. An unusual cause of dyspnoea in a patient with chronic ischemic heart disease. *APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche* 2018;106:A4(1-5).
66. Cannavò MF, Picciolo S, Chillè G, Quattrocchi P, Gangemi S, Coppolino I, Ruggeri P, **Caramori G**. An elderly man with congenital hypogammaglobulinemia and persistent cough. *Atti dell'Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche* 2019;107.
67. Cipolla G, Sacco A, Proietto A, Relo R, Ruggeri P, **Caramori G**. A middle-age non-smoking woman with uncontrolled persistent bronchial asthma. *Atti dell'Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche* 2019;107
68. Bellanti MT, Coppolino I, Proietto A, Picciolo S, Relo R, Chillè G, Salamone I, Ruggeri P, **Caramori G**. A patient with acute hypoxemic respiratory failure and diffuse alveolar hemorrhage syndrome. *APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche* 2019;107(2):SS1(1-4).
69. Cotroneo A, Zompatori M, Familiari D, Monaco F, Coppolino I, Lo Bello F, Nucera F, Proietto A, Salamone I, Ruggeri P, Harari S, **Caramori G**. An unusual case of chronic

airflow obstruction in a heavy smoker. APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche 2020;108(1):CCS4(1-4).

70. Catalano D, Proietto A, Salamone I, Picciolo S, Relo R, Lo Bello F, Nucera F, Coppolino I, Chillè G, Ruggeri P, **Caramori G**. A case of fibrosing interstitial pneumonia. APMB - Atti della Accademia Peloritana dei Pericolanti Classe di Scienze Medico Biologiche 2020;108(1):CCS1(1-5).

71. Catalano D, Ruggeri P, Salamone I, **Caramori G**. Polmonite interstiziale fibrosante da amiodarone. L'Endocrinologo 2020;21:78-80.

72. Braccioni F, Coppolino I, Vito S, Pezzuto F, Lo Bello F, Foltran G, Alberti S, Vianello A, **Caramori G**. Exogenous chronic lipid pneumonia: a case report. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2020;108(2):1-6.

73. Tuccari G, **Caramori G**, Cavallari V, Fadda G, Ieni A. Lungs of COVID-19 affected patients: an autoptic morphological profile. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2020;108(2):1-8.

74. Di Stefano A, Carriero V, Bertolini F, Dossena F, Maniscalco M, **Caramori G**, Ricciardolo FLM. Caratteristiche patologiche dell'asma. Parte I. Rass Patol App Respir 2021;36:206-214.

75. Zappalà A, Puglisi S, Di Cataldo I, Trombetta A, Lo Bello F, Proietto A, Coppolino I, Poletti V, **Caramori G**. An unusual non-resolving community-acquired pneumonia. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2021;109(2):1-6.

76. Di Stefano A, Carriero V, Bertolini F, Dossena F, Maniscalco M, **Caramori G**, Ricciardolo FLM. Caratteristiche patologiche dell'asma. Parte I. Rass Patol App Respir 2022;37:3-10.

77. Trombetta A, Zappalà A, Di Cataldo I, Relo R, Lo Bello F, Proietto A, **Caramori G**. Drowning with acute respiratory failure. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2022;110(1):1-9.

78. Nucera F, Salvato I, Ricciardi L, Nigro A, Dal Col J, Monaco F, Ieni A, Fadda G, Tuccari G, Stellato C, **Caramori G**. Role of RNA-binding proteins in both COPD and lung cancer. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2022;110(2):1-12.

79. Cipolla A, Faiello A, Ielo G, Morana G, , Lo Bello F, Proietto A, Vancheri C, **Caramori G**. An unusual association in a patient with COVID-19-related ARDS and bilateral pleural effusion. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2023;111(1):1-7.

80. Renda A, Alessio Trombetta, Andrea Zappalà, Alfio Proietto, Antonio Faiello, Rosalba Relo, Federica Lo Bello, Paola Maria Cutroneo, Antonio Ieni, Giuseppe Mancuso, Guido Fadda, Francesco Monaco, **Caramori G**. A rare cause of pneumonia in an immunocompromised patient. Atti della Accademia Peloritana dei Pericolanti, Classe di Scienze Medico-Biologiche; 2023;111(2):1-7.

81. Scotto D, Antenora F, Secondo O, Montanaro V, Valzano I, Alfieri V, Pagani M, Aiello M, **Caramori G**, Majori M. Localizzazione tracheale di neoplasia ovarica: rara condizione clinica quasi fatale. Rass Patol App Respir 2024;39:200-202  
doi: 10.36166/2531-4920-787.

82. Montana A, Aiello M, Aredano I, Bonini A, Burgazzi B, D'Addona CD, Leopizzi C, Longo C, Longo F, Rossi F, Pagliarini M, Piemontese G, Tessitore C, Bertorelli G, Majori M, **Caramori G**. Severa polmonite verosimilmente iatrogena simulante una CAP in paziente affetto da carcinoma polmonare non a piccole cellule in stadio avanzato. Rass Patol App Respir 2025;40:87-92.

### c. Proceedings of International Meetings

1. Fabbri LM, **Caramori G**, Ciaccia A. Future management of asthma. In: Manresa F. Long-acting  $\beta_2$ -agonists: issues and challenges. Ciba International Symposium Series vol 1, London, Parthenon Publishing Group, 1996:9-15.
2. Fabbri LM, **Caramori G**, Facchini FM, Ciaccia A. Anti-inflammatory treatments for asthma: past, present, future. In: Chanez P, et al. From genetics to quality of life. Proceedings of the Xvth World Congress of Asthmology, Montpellier, April 24-27, 1996, Bern, Hoegrefe and Huber publishers, 1996:134-141.
3. Papi A, Beghè B, **Caramori G**, Ciaccia A, Fabbri LM. The future of relievers and controllers in asthma therapy. In: Kummer F. Treatment of asthma: the long-acting beta-2-agonists. Wien, Springer-Verlag, 1998:165-182.
4. Papi A, Braccioni F, **Caramori G**, Fabbri LM. Evidence for oral therapeutic interventions in asthma. *Eur Respir Rev* 1998;8:317-321.
5. Papi A, **Caramori G**, Fabbri LM. Current asthma therapies and issues in asthma management. *Eur Respir Rev* 1998;8:341-347.
6. Papi A, Guzzinati I, **Caramori G**, Fabbri LM. The complexity of asthma phenotype. *Eur Respir Rev* 1998;8:1020-1023.
7. Papi A, **Caramori G**, Fabbri LM. Evaluation by self-monitoring and noninvasive measures. *Eur Respir Rev* 2000;10:45-49.

#### **d. Proceedings of National Meetings**

1. Fabbri L, **Caramori G**, Ciaccia A. Le linee guida vengono seguite?. In: Atti del III Incontro teorico-pratico di Aggiornamento su Temi di Pneumoallergologia. Napoli 5-6 dicembre 1996.
2. Beghè B, **Caramori G**, Fabbri L. Genetica dell'asma bronchiale. In: Atti delle Giornate Retiche di Pneumologia. Como, 7-8 novembre 1996.
3. Fabbri L, **Caramori G**, Ciaccia A. La terapia steroidea. In: Atti del 1° Convegno Nazionale S.I.Me.R. di Aggiornamento in Pneumologia. Napoli 14-15 novembre 1997:33-43.
4. Fabbri L, Beghè B, **Caramori G**, Ciaccia A. Fattori genetici nell'asma e nella BPCO. In: Atti del Congresso Nazionale su Inquinamento dell'aria e patologie respiratorie. Lecce 26-28 febbraio 1998, Editoriale Arnando Folini 1998:137-143.
5. Fabbri L, **Caramori G**, Beghè B, Ciaccia A. Controversie in tema di terapia dell'asma e della BPCO. In: Atti del Congresso Nazionale su Inquinamento dell'aria e patologie respiratorie. Lecce 26-28 febbraio 1998, Editoriale Arnando Folini 1998:421-428.
6. Ciaccia A, Papi A, **Caramori G**, Beghè B, Fabbri L. Ossidanti ed antiossidanti nella patologia respiratoria. In: Atti del Congresso Nazionale su Inquinamento dell'aria e patologie respiratorie. Lecce 26-28 febbraio 1998, Editoriale Arnando Folini 1998:126-132.
7. Fabbri L, **Caramori G**, Beghè B, Ciaccia A. Asma e leucotrieni. In: Atti del Congresso Nazionale su Inquinamento dell'aria e patologie respiratorie. Lecce 26-28 febbraio 1998, Editoriale Arnando Folini 1998:354-355.

#### **e. International book chapters**

1. Fabbri LM, **Caramori G**, Maestrelli P. Definition, clinical features, investigations and differential diagnosis in asthma. In: Kay AB. Allergy and allergic diseases. 2 vol, Oxford, Blackwell Science 1997:1343-1356.
2. Fabbri L, **Caramori G**, Maestrelli P. Etiology of occupational asthma. In: Sipes GI, McQueen CA, Gandolfi AJ. Comprehensive toxicology. Volume 8. Toxicology of the respiratory system. Oxford, Elsevier Science 1997;:425-435.

3. Fabbri L, **Caramori G**, Piattella M, Maestrelli P. Neutrophils. In: Asthma. Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ. Asthma. New York, Lippincott-Raven 1997:419-432.
4. Catena E, Simone G, **Caramori G**, Ciaccia A. Extrapulmonary tuberculosis. In: Wilson R. Tuberculosis. European Respiratory Monograph 1997;2:175-194.
5. Fabbri L, **Caramori G**, Beghè B, Mapp C. Intrinsic asthma. In: Szczeklik A. Eicosanoids, aspirin and asthma. Lung biology in health and disease series, vol 114, New York, Marcel Dekker 1998;215-229.
6. Fabbri L, Boschetto P, **Caramori G**, Maestrelli P. Neutrophils and asthma. In: Busse W, Kay B, Holgate S. Inflammatory mechanisms of asthma. Lung biology in health and disease series, vol 117, New York, Informa HealthCare 1998;287-322.
7. Fabbri L, Boschetto P, **Caramori G**, Mapp CE. Pathophysiology. In: Bernstein II, Chan-Yeung M, Malo J-L, Bernstein DI. Asthma in the workplace. 2<sup>nd</sup> ed, New York, Marcel Dekker 1999;81-109.
8. Papi A, Boschetto P, **Caramori G**, Fabbri LM. Neutrophils and asthma. In: Busse W, Holgate S. Asthma and rhinitis. Blackwell, London, 2000:518-530.
9. Adcock I, **Caramori G**. Therapies acting on transcription: overview. In: Hansel TT, Barnes PJ. New drugs for asthma, allergy and COPD. Progress in Respiratory Research, vol 31. Basel, Karger Publishers, 2001:328-331.
10. Adcock I, **Caramori G**. Transcription factors in asthma and COPD. In: Barnes PJ, Drazen J, Rennard S, Thomson NC. Asthma and COPD: basic mechanisms and clinical management. London, Academic Press, 2002:315-321.
11. Papi A, **Caramori G**, Adcock IM, Johnston S. Molecular mechanisms of respiratory virus-induced inflammation. In: Johnston S, Papadopoulos N. Respiratory viral infections. Lung biology in health and disease series, vol 178, New York, Marcel Dekker 2003:210-228.
12. Casoni G, **Caramori G**, Papadopoulos N, Johnston S, Papi A. Gender and respiratory infections. Eur Respir Mon 2003;25:1-14.
13. **Caramori G**, Adcock IM. Corticosteroids: basic pharmacology. In: Cazzola M, Celli B, Dahl R, Rennard S. Therapeutic strategies in COPD. Clinical Publishing, London 2005:151-167.
14. Papi A, Chicca M, Pandit A, **Caramori G**. Oxidants and antioxidants. Antioxidants, nonenzymatic. In: Encyclopedia of Respiratory Medicine. Elsevier, London 2006;266-271.
15. Adcock IM, Ito K, **Caramori G**. Transcription factors: overview. In: Encyclopedia of Respiratory Medicine. Elsevier, London 2006;243-251.
16. Adcock IM, Hayashi R, Ito K, **Caramori G**. Corticosteroids: glucocorticoid receptors. In: Encyclopedia of Respiratory Medicine. Elsevier, London 2006;568-576.
17. **Caramori G**, Ito K, Papi A. Steroid-sparing strategies: other combinations. In: Chung KF, Adcock IM. Overcoming Steroid Insensitivity in Respiratory Disease. London, John Wiley and Sons; 2008:187-206.
18. Maestrelli P, **Caramori G**, Franco F, Fabbri LM. Definition, clinical features, investigations and differential diagnosis in asthma. In: Kay AB, Bousquet J, Holt P, Kaplan AP. Allergy and allergic diseases. 2 vol, 2<sup>nd</sup> ed, London, Blackwell Publishing 2008:1597-1620.
19. Contoli M, **Caramori G**, Marku B, Pandit A, Papi A. Interactions of airway pathogens and inflammatory process. In: Wedzicha W, Martinez F. Exacerbations of chronic obstructive pulmonary disease (COPD). 1<sup>st</sup> edition. Lung biology in health and disease series, vol 228, Informa HealthCare, London 2008:129-137.
20. Adcock I, **Caramori G**. Transcription factors in asthma and COPD. In: Barnes PJ, Drazen J, Rennard S, Thomson NC. Asthma and COPD: basic mechanisms and clinical management. London, Academic Press, 2008:367-374.

21. **Caramori G**, Adcock IM, Papi A. COPD exacerbations: definition and classifications. In: Cazzola M, Sethi S, Blasi F, Anzueto A. Therapeutic strategies in acute exacerbations in COPD. Clinical Publishing Company, London UK 2009: 1-12.
22. **Caramori G**, Ito K, Casolari P, Papi A, Adcock IM. Targeting Th2 cells in asthmatic airways. In: Pawankar R, Holgate S, Rossenwasser L. Allergy frontiers: from epigenetics to future perspectives. Vol 6. Springer Japan, 2009:103-148.
23. Adcock IM, Chung KF, **Caramori G**. Inhaled corticosteroids in airways disease. In: Pharmacology and therapeutics of airways diseases, Second Edition (Lung Biology in Health and Disease series, vol 234). Edited by Kian Fan Chung and Peter J Barnes. New York, Informa Healthcare, 2010:162-197.
24. Kirkham P, **Caramori G**, Chung KF, Adcock IM. Novel anti-inflammatory treatments for asthma and COPD. In: Advances in Combination Therapy for Asthma and COPD, First Edition. Edited by Jan Lotvall. London, John Wiley & Sons, Ltd, 2011:154-202.
25. **Caramori G**, Casolari P, Garofano E, Baart I, Contoli M, Mazzoni F, Adcock IM, Papi A. Role of stem cells in the pathogenesis of COPD and pulmonary emphysema. In: Hayat MA (Ed). Stem Cells and Cancer Stem Cells, Volume 6. In: Therapeutic Applications in Disease and Injury Series. Springer Netherlands, 2012:307-317.
26. **Caramori G**, Contoli M, Marku B, Casolari P, Pauletti A, Forini G, Papi A. Definition and aetiology of infective exacerbations of COPD. Eur Respir Monogr 2013;60:58-67.
27. **Caramori G**, Ruggeri P, Mumby S, Atzeni F, Adcock, IM (Feb 2019) Transcription Factors. In: eLS. John Wiley & Sons Ltd, Chichester. <http://www.els.net> [doi: 10.1002/9780470015902.a0005278.pub3].
28. **Caramori G**, Mumby S, Girbino G, Chung KF, Adcock, IM. Corticosteroids. In: Parnham MJ, Nijkamp FP, Rossi AG (eds). Nijkamp and Parnham's Principles of Immunopharmacology.4<sup>th</sup> extended and revised edition. Springer International Publishing AG 2019:661-688.
29. **Caramori G**, Adcock, IM, Barnes PJ, Chung KF,. Drugs for the Treatment of Airway Disease. In: Parnham MJ, Nijkamp FP, Rossi AG (eds). Nijkamp and Parnham's Principles of Immunopharmacology.4<sup>th</sup> extended and revised edition. Springer International Publishing AG 2019:425-474.
30. Di Cataldo I, Proietto A, Coppolino I, Cannavò MF, Cotroneo A, Lo Bello F, Ruggeri P, Adcock IM and **Caramori G**. Bacterial infections in the lungs of patients with systemic autoimmune diseases. In: Handbook of Systemic Autoimmune Diseases, Volume 16. Infections in Systemic Autoimmune Diseases: Risk Factors and Management. Elsevier, London, 2020:1-11. ISBN: 9780444642172.
31. **Caramori G**, Nucera F, Coppolino I, Lo Bello F, Ruggeri P, Kazuhiro I, Di Stefano A, Adcock IM. Transcription Factors. In: Encyclopedia of Respiratory Medicine, 2nd edition. Elsevier, London (2022) (<https://www.sciencedirect.com/referencework/9780081027240/encyclopedia-of-respiratory-medicine>).
32. Di Stefano A, Carriero V, Bertolini F, **Caramori G**, Ricciardolo FLM. Pathology of Asthma. In: Encyclopedia of Respiratory Medicine, 2nd edition. Elsevier, London (2022). (<https://www.sciencedirect.com/referencework/9780081027240/encyclopedia-of-respiratory-medicine>)
33. Cannavò MF, Coppolino I, Monaco F, **Caramori G**. Overview of current management of COPD. In: Encyclopedia of Respiratory Medicine, 2nd edition. Elsevier, London (2022) (<https://www.sciencedirect.com/referencework/9780081027240/encyclopedia-of-respiratory-medicine>)
34. Nucera F, Hansbro PM, Casolaro V, Appanna R, Kirkham P, Adcock IM, **Caramori G**. Role of autoimmunity in the pathogenesis of chronic obstructive pulmonary disease and

pulmonary emphysema. *Translational Immunology Book*. 2022 Vol 3. Chapter 14, 312—330.

35. Nucera F, Hansbro PM, Fairley LH, Monaco F, Uwagboed I, Mumby S, Adcock IM, **Caramori G**. Stem Cells/Lung Organoids and Lung Rejuvenation in the Treatment of Chronic Obstructive Pulmonary Disease and Pulmonary Emphysema. *Comprehensive Hematology and Stem Cell Research* (Editor-in-Chief: Nima Rezaei). Reference Work • First Edition • 2024, Elsevier (<https://www.sciencedirect.com/referencework/9780443157189/comprehensive-hematology-and-stem-cell-research>).

#### **h. National book chapters**

1. Fabbri LM, **Caramori G**, Saetta M, Ciaccia A. Corticosteroidi, disodiocromoglicato e nedocromile nella terapia dell'asma bronchiale e delle broncopneumopatie croniche ostruttive. In: Olivieri D, Bianco S, Folco GC (Ed). *Il Punto su asma e BPCO: similitudini e differenze*. Scientific Press, 1995:261-277.
2. Fabbri LM, Ferrari M, **Caramori G**, Ciaccia A. Broncodilatatori e glucocorticoidi nella terapia delle broncopneumopatie croniche ostruttive. In: Grassi C, Luisetti M. *Pneumologia '90. Insufficienza respiratoria cronica: storia naturale e momenti di intervento terapeutico*. Pavia, Edizioni Medico-Scientifiche 1995:149-170.
3. **Caramori G**, Panella GL, Piattella G, Fabbri LM. Patogenesi dell'asma bronchiale. In: Allegra L. *L'asma e l'asmatico: stato dell'arte e linee guida dell'asma*. Bologna, Editeam, 1997.
4. Reggiani C, Polla B, **Caramori G**, Consonni D, Fabbri LM. Delivery systems e protocollo di Montreal. Casalnoceto (Alessandria), Editoriale Fernando Folini 1997.
5. Beghè B, **Caramori G**, Fabbri LM, Ciaccia A. Il futuro nella terapia dell'asma. In: De Palma M, Grassi C. *Rapporto sull'asma*. Milano, Syntagma srl 1997:213-226.
6. Fabbri LM, Piattella M, **Caramori G**, Ciaccia A. Polmoniti da parassiti. In: Gritti F, Milazzo S, Poletti V. *Polmoniti infettive*. Milano, McGraw Hill Italia 1998:341-363.
7. Fabbri LM, **Caramori G**, Ciaccia A. Glucocorticoidi. In: Berti F, Folco G, Olivieri D (Eds). *Farmacologia e terapia dell'apparato respiratorio*. Torino, Utet, 1998:36-46.
8. **Caramori G**, Papi A, Fabbri LM. Patogenesi delle broncopneumopatie croniche ostruttive. In: Fabbri LM, Ciaccia A (Ed). *Broncopneumopatie croniche ostruttive*. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 1999:57-71.
9. **Caramori G**, Papi A, Fabbri LM. Patogenesi delle broncopneumopatie croniche ostruttive. In: Fabbri LM, Ciaccia A (Ed). *Broncopneumopatie croniche ostruttive*. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 1999:57-71.
10. Papi A, **Caramori G**, Pinamonti S, Ciaccia A. Ossidanti ed antiossidanti nelle broncopneumopatie croniche ostruttive. In: Fabbri LM, Ciaccia A (Ed). *Broncopneumopatie croniche ostruttive*. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 1999:99-116.
11. **Caramori G**, Corbetta L, Fabbri LM, Ciaccia A. Manifestazioni cliniche delle broncopneumopatie croniche ostruttive. In: Fabbri LM, Ciaccia A (Ed). *Broncopneumopatie croniche ostruttive*. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 1999:127-137.
12. **Caramori G**, Romagnoli M, Fabbri LM. Protocolli di trattamento farmacologico delle broncopneumopatie croniche ostruttive. In: Fabbri LM, Ciaccia A (Ed). *Broncopneumopatie croniche ostruttive*. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 1999:189-197.

13. **Caramori G**, Ito K, Tomita K, Barnes PJ, Adcock IM. Fattori di trascrizione ed asma bronchiale. In: Fabbri LM (Ed). Asma bronchiale. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 2000:151-176.
14. Papi A, Casoni G, **Caramori G**, Ciaccia A, Fabbri LM. Infezioni virali ed asma bronchiale. In: Fabbri LM (Ed). Asma bronchiale. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 2000:63-79.
15. Paredi P, **Caramori G**, Mozzi C, Kharitonov SA, Barnes PJ. Misure non invasive di infiammazione bronchiale. In: Fabbri LM(Ed). Asma bronchiale. Collana monografica AIPO, Pisa, Edi-AIPO Scientifica 2000:235-252.
16. **Caramori G**, Roggeri A, Papi A, Castiglione MT, Papi A, Ciaccia A. Parassiti e polmoni. In: Donner CF, Sanguinetti CM (Ed). Trattato Italiano di Pneumologia, vol 2, Pisa, Edi-AIPO Scientifica 2001;1077-1106.
17. Ciaccia A, **Caramori G**, Papi A. Malattie polmonari primitive da cause dismetaboliche. In: Casali L. Manuale di Malattie dell'Apparato Respiratorio. Milano, Masson Italia, 2001;503-508.
18. **Caramori G**, Fabbri LM. Diagnosi, diagnosi differenziale, misura di gravità ed impostazione terapeutica in fase stabile. In: Grassi C. Progressi in Pneumologia: continuing medical education 2001. Roma, CEPI, 2002;21-47.
19. **Caramori G**, Fabbri LM. Diagnosi, diagnosi differenziale, misura di gravità ed impostazione terapeutica delle riacutizzazioni. In: Grassi C. Progressi in Pneumologia: continuing medical education 2001. Roma, CEPI, 2002;49-61.
20. Ciaccia A, Papi A, **Caramori G**, Fabbri LM. Patologia vascolare polmonare. In: Crepaldi G (Ed). Trattato di Medicina Interna. Piccin Editore, 2002: chapter 168.
21. Fabbri LM, **Caramori G**, Papi A, Beghè B, Ciaccia A. Asma. In: Crepaldi G (Ed). Trattato di Medicina Interna. Piccin Editore, 2002: chapter 171.
21. Ciaccia A, **Caramori G**, Guzzinati I, Papi A. Malattie della pleura. In: Zuin R (ed). Malattie dell'Apparato Respiratorio. In: Larizza P. Trattato di Medicina Interna. Padova, Piccin 2008: 1215-1264.
22. **Caramori G**, Papi A. Infezioni acute delle vie aeree. In: Gasbarrini (Eds). Trattato di Medicina Interna. Roma, Verduci Editore, 2011:1019-1038.
23. **Caramori G**, Marku B, Papi A. Malattie virali dell'apparato respiratorio. In: Fabbri LM, Marsico S (Eds). Trattato di malattie respiratorie. Napoli, Edises, 2013:190-205.

#### **i. Scientific translations from English into Italian**

1. Sheffer AL. (Ed). Global Initiative for Asthma. NHLBI/WHO Workshop report. National Institutes of Health, National Heart, Lung and Blood Institute. Publication No. 95-3659. January 1995.
2. Italian Edition of the European Respiratory Journal (1997-2001 by Momento Medico s.r.l, Salerno, Italy)

#### **I. Electronic publications only**

##### **WWW-based**

1. **Caramori G**, Fabbri L. Immunomodulators should still be considered experimental drugs for the treatment of systemic glucocorticoid dependent severe persistent asthma?. Asmanet (posted 21/07/98). <http://www.remcomp.com/asmanet/fabbri97.html>
2. **Caramori G**, Papi A, Ciaccia A. Broncodilatatori nella terapia delle broncopneumopatie croniche ostruttive. 2004. Available online at <http://www.medsolve.it>


##### **CDrom**

1. Asma bronchiale. CDrom per il Medico di Medicina Generale. Milano, RGB srl, 1997.
2. **Caramori G**, Fabbri L, Caraffa G. Asma bronchiale. CDrom per lo Specialista in Malattie dell'Apparato Respiratorio. Milano, RGB srl, 1997.

*12th of February 2026*

*I hereby grant permission to use my personal data in accordance with the Italian Art.13, Legislative Decree n. 196/03- "Personal Data Protection Code" and the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016.*

*Prof Gaetano Caramori*

A handwritten signature in black ink, reading "Gaetano Caramori". The signature is written in a cursive style with a large initial 'G'.